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Abstract
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF) was requested to deliver a scientiﬁc opinion on the
safety assessment of the ﬂavouring substances caffeine [FL-no: 16.016] and theobromine [FL-no:
16.032] in the Flavouring Group Evaluation 49, Revision 1. Consequent to the 2015 scientiﬁc opinion
from the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on the safety of caffeine from all
dietary sources, the CEF Panel considered it inappropriate to evaluate the two substances through the
Procedure. For caffeine, the Panel based its assessment on the safety threshold of 5.7 mg/kg body
weight (bw) per day for adults, except pregnant/lactating women, and 3 mg/kg bw per day for children,
adolescents, pregnant and lactating women, as established by the NDA Panel. The safety evaluation of
theobromine takes into account that approximately 11% of an oral dose of caffeine is metabolised to
theobromine and that both substances have a similar pharmacological proﬁle. For the exposure
assessment, a brand loyalty model was chosen. In this model, it was assumed that a consumer is
exposed on a long-term basis to a speciﬁc category of food (i.e. non-alcoholic beverages), containing
caffeine or theobromine at their respective maximum use levels. For the rest of the categories, normal
use levels applied. Daily dietary exposure to caffeine and theobromine (excluding systemic exposure)
added as a chemically deﬁned ﬂavouring substance ranged 0–2.3 and 0–0.4 mg/kg bw, respectively,
across all population groups. The Panel concluded that caffeine [FL-no: 16.016] and theobromine [FL-no:
16.032] would not be expected to present safety concern based on their estimated levels of intake from
their use as ﬂavouring substances.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 2232/96 of the European Parliament and the Council1 lays down a Procedure for
the establishment of a list of ﬂavouring substances, the use of which will be authorised to the exclusion
of all other substances in the European Union (EU). In application of that Regulation, a Register of
ﬂavouring substances used in or on foodstuffs in the Member States was adopted by Commission
Decision 1999/217/EC2, as last amended by Commission Decision 2008/478/EC. Each ﬂavouring
substance is attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical
groups. Substances within a group should have some metabolic and biological behaviour in common.
Substances which are listed in the Register are to be evaluated according to the evaluation
programme laid down in Commission Regulation (EC) No 1565/20003, which is broadly based on the
opinion of the Scientiﬁc Committee on Food (SCF, 1999). For the submission of data by the
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002.
After the completion of the evaluation programme the positive list of ﬂavouring substances for use
in or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96).
By Commission Decision 1999/217/EC, certain ﬂavouring substances received priority in the
evaluation programme, since concerns about the safety of the health of consumers were expressed by
some Member States. In the Register, these substances received the following remark: 3. ‘Substance
to be given priority evaluation’.
In the Commission Decision 1999/217/EC, Parts 1–3, 18 ﬂavouring substances received this remark.
In May 2000, a revised list containing 49 ﬂavouring substances with this remark was adopted
(Commission Decision 2000/489/EC amending Commission Decision 1999/217/EC). By the amendment
from January 2002 (Commission Decision 2002/113/EC amending Commission Decision 1999/217/EC),
the list contains 43 ﬂavouring substances with this remark (see Table 1).
Table 1: Status of 43 Flavouring Substances Given Priority Evaluation (in Commission Decision
2002/113/EC amending Commission Decision 1999/217/EC)
FL-no Name Status in the FLAVIS database, May 2008
01.015 Vinylbenzene FGE.29 – Priority substance
08.017 Malic acid JECFA-no: 619
08.041 Octadeca-9,12-dienoic
acid
JECFA-no: 332
13.018 Furfural EFSA opinion adopted 2004. ADI of 0.5 mg/kg bw. FGE.19 – EFSA evaluation of
alpha,beta-unsaturated aldehydes and ketones under evaluation
13.035 Menthofuran FGE.57 – EFSA consideration of JECFA evaluated substances – under evaluation
13.126 Furfural diethyl acetal EFSA opinion adopted 2004. ADI of 0.5 mg/kg bw. FGE.19 – EFSA evaluation of
alpha,beta-unsaturated aldehydes and ketones under evaluation
14.011 Quinine hydrochloride FGE.35 – JECFA evaluation 1993: No concern up to 100 mg/L in soft drink
(Commission Directive 2002/67/EC)
14.152 Quinine sulfate FGE.35 – JECFA evaluation 1993: No concern up to 100 mg/L in soft drink
(Commission Directive 2002/67/EC)
14.155 Quinine
monohydrochloride
dihydrate
FGE.35 – JECFA evaluation 1993: No concern up to 100 mg/L in soft drink
(Commission Directive 2002/67/EC)
16.002 Diammonium sulﬁde Not allocated any evaluation – suggested for deletion by DG SANCO
16.012 Glycyrrhizic acid FGE.36 – SCF opinion adopted 2003 (Commission Directive 2004/77/EC). JECFA
evaluation 2004: Data were inadequate to derive an ADI
16.016 Caffeine FGE.49 – SCF opinions adopted 1999, 2003 (Commission Directive 2002/67/EC)
1 Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996. Ofﬁcial Journal of the
European Communities 23.11.1996, L 299, 1–4.
2 Commission Decision 1999/217/EC of 23 February 1999 adopting a register of ﬂavouring substances used in or on foodstuffs.
Ofﬁcial Journal of the European Communities 27.3.1999, L 84, 1–137.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation (EC) No 2232/96. Ofﬁcial Journal of the European Communities 19.7.2000, L 180, 8–16.
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Of the 43 substances in Table 1, one is suggested for deletion from the Register, 12 have been
evaluated in other Flavouring Group Evaluations (FGEs), and 22 have been evaluated by The Joint
FAO/WHO Expert Committee on Food Additives (JECFA) (20 of these JECFA evaluated substances are
also considered by EFSA).
The remaining eight substances, vinylbenzene [FL-no: 01.015], quinine hydrochloride [FL-no:
14.011], quinine sulfate [FL-no: 14.152], quinine monohydrochloride dihydrate [FL-no: 14.155],
glycyrrhizic acid [FL-no: 16.012], glycyrrhizic acid, ammoniated [FL-no: 16.060], caffeine [FL-no:
16.016] and theobromine [FL-no: 16.032] are considered in the following Flavouring Group Evaluations:
FGE.29: Aromatic hydrocarbon: vinylbenzene [FL-no: 01.015];
FGE.35: Quinoline alkaloids: quinine hydrochloride [FL-no: 14.011], quinine sulfate [FL-no: 14.152],
quinine monohydrochloride dihydrate [FL-no: 14.155];
FGE.36: Triterpene glycosides: glycyrrhizic acid [FL-no: 16.012], glycyrrhizic acid, ammoniated [FL-no:
16.060];
FGE.49: Xanthine alkaloids: caffeine [FL-no: 16.016] and theobromine [FL-no: 16.032].
FL-no Name Status in the FLAVIS database, May 2008
16.027 Thiamine
hydrochloride
FGE.76 – Adopted EFSA consideration of JECFA evaluated substances
16.032 Theobromine FGE.49 – SCF opinions adopted 1999, 2003 on caffeine
16.056 Taurine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
16.059 Ammonium hydrogen
sulﬁde
FGE.46 – EFSA evaluation of ammonium and ammonium salts under evaluation
16.060 Glycyrrhizic acid,
ammoniated
FGE.36 – SCF opinion adopted 2003 (Commission Directive 2004/77/EC). JECFA
evaluation 2004: Data were inadequate to derive an ADI
17.001 b-Alanine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.002 l-Alanine FGE.26Rev1 – Adopted EFSA evaluation of amino acids
17.003 Arginine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.005 Aspartic acid FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.006 Cystine FGE.26 – Adopted EFSA evaluation of amino acids
17.007 Glutamine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.008 Histidine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.010 Isoleucine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.012 Leucine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.013 Lysine FGE.26 – Adopted EFSA evaluation of amino acids
17.014 Methionine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.017 Phenylalanine (D,L) FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.018 Phenylalanine (L) FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.019 Proline FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.020 Serine FGE.26 – Adopted EFSA evaluation of amino acids
17.021 Threonine FGE.26 – Adopted EFSA evaluation of amino acids
17.022 Tyrosine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.023 Valine (D,L) FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.024 Alanine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.026 Lysine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.027 Methionine FGE.26Rev1 – Adopted EFSA evaluation of amino acids
17.028 Valine (L) FGE.26Rev1 – Adopted EFSA evaluation of amino acids
17.031 Lysine
monochlorhydrate
FGE.26 – Adopted EFSA evaluation of amino acids
17.032 Cysteine hydrochloride FGE.26Rev1 – Adopted EFSA evaluation of amino acids
17.033 Cysteine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
17.034 Glycine FGE.79 – Adopted EFSA consideration of JECFA evaluated substances
FL-no: FLAVIS number; FLAVIS: Flavour Information System; FGE: Flavouring Group Evaluation; JECFA: The Joint FAO/WHO
Expert Committee on Food Additives; ADI: acceptable daily intake; bw: body weight; SCF: Scientiﬁc Committee on Food.
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Terms of Reference as provided by the European Commission
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on
ﬂavouring substances prior to their authorisation and inclusion in a positive list according to
Commission Regulation (EC) No 1565/2000.
1.2. Interpretation of the Terms of Reference
The safety of the xanthine alkaloids caffeine and theobromine was considered in a previous version of
this FGE (EFSA, 2009); however, the assessment could not be ﬁnalised. The current revision includes
newly submitted information as well as the results of an extensive safety assessment of caffeine
undertaken by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel), published in
2015 (EFSA NDA Panel, 2015).
2. Assessment
2.1. History of the evaluation of the substances in the present FGE
(Table 2)
The Flavouring Group Evaluation 49, FGE.49 concerns the two xanthine alkaloids from the EU
chemical group 30, Annex I of Commission Regulation (EC) No 1565/20003: caffeine [FL-no: 16.016]
and theobromine [FL-no: 16.032].
Typically, in line with Regulation (EC) No 1565/2000, for the initial evaluation of ﬂavouring
substances the Panel applies as a standard the Maximised Survey-derived Daily Intake (MSDI)
approach to assess exposure. This involves the acquisition of data on the amounts of the substances
used in food as ﬂavourings (SCF, 1999) which are derived from surveys on annual production volumes
in Europe, conducted by the International Organization of the Flavour Industry (IOFI, 1995).
In 2008, as information on production volumes allowing for the derivation of then MSDI was not
available (EFSA, 2009), the Panel concluded that the two ﬂavouring substances could not be evaluated
using the Procedure described in Regulation (EC) No 1565/2000 (hereafter ‘the Procedure’).
In 2010, the ﬂavour industry submitted the requested information on production volumes and data
on normal and maximum use levels for the two substances caffeine [FL-no: 16.016] and theobromine
[FL-no: 16.032] (Flavour Industry, 2010), allowing for the evaluation of the two ﬂavouring substances
according to the Procedure (see Appendix A). However, in the light of the scientiﬁc opinion on the
safety of caffeine issued by the NDA Panel (EFSA NDA Panel, 2015), the CEF Panel decided not to
follow the Procedure for the safety evaluation of the two ﬂavouring substances (see Section 2.2).
2.2. Evaluation approach
The safety of caffeine from all sources was previously evaluated by the SCF in 1999 and 2003 (see
Appendix H). More recently, an extensive evaluation of caffeine from all major sources was undertaken
by the NDA Panel (EFSA NDA Panel, 2015). Therefore, the CEF Panel considered it inappropriate to
evaluate caffeine through the Procedure for the evaluation of chemically deﬁned ﬂavouring substances
(see Appendix A) and instead chose to build on the NDA opinion for the revised evaluation of caffeine.
Like for caffeine, the Panel decided not to evaluate theobromine through the Procedure, but to
base its assessment on the fact that theobromine is a major metabolite of caffeine. Thus, the
information available on the safety of caffeine in the NDA opinion could also be used for the safety
assessment of this substance, for which only limited toxicity data in humans are available. The
scientiﬁc opinion from the EFSA Panel on Contaminants in the Food Chain (EFSA CONTAM Panel)
(EFSA, 2008) on the presence of theobromine as undesirable substance in animal feed was also not
Table 2: History of safety evaluations concerning FGE.49
FGE
Opinion adopted
by EFSA
Link
No. of candidate
substances
FGE.49 22 May 2008 http://www.efsa.europa.eu/en/efsajournal/doc/741.pdf 2
FGE.49Rev1 31 January 2017 http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.
4729/full
2
FGE: Flavouring Group Evaluation.
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used as a basis for the safety evaluation of theobromine in the present opinion, since it does not
provide a point of departure for quantitative risk assessment on the safety of theobromine in human
food.
Consequently, the Panel decided to structure this opinion in a different way than the one typically
used for other Flavouring Group Evaluations, in which the Procedure for the safety evaluation of
ﬂavouring substances is applied (described in Appendix A).
2.3. Identiﬁcation of the ﬂavouring substances
The two ﬂavouring substances under consideration, as well as their chemical Register names,
FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract
Manufacturers Association- (FEMA-) numbers and structure are listed in Table 3. Speciﬁcations,
including purity criteria for the two substances are also provided (Flavour Industry, 2010).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000, the
information is adequate for the two candidate substances (Table 3).
2.4. Exposure assessment
2.4.1. Introduction
To assess exposure to caffeine and theobromine as chemically deﬁned ﬂavouring substances in
food, the CEF Panel decided to consider the information available in the NDA opinion on the safety of
caffeine (EFSA NDA Panel, 2015) for the following reasons:
• To take advantage of the extensive evaluation carried out by the NDA Panel and to be
consistent with its output.
• To investigate the contribution of the intake from ﬂavouring use to the exposure from all
dietary sources.
For the purposes of this assessment, the Panel derived exposure estimates for (i) each of the
chemically deﬁned ﬂavouring substances caffeine and theobromine when directly added to food and
(ii) total exposure to each of these substances from all sources, taking into account natural occurrence
and intentional use. The combined exposure to theobromine from intake of theobromine as such and
from intake of caffeine was also assessed. In this assessment, systemic exposure to theobromine as
metabolite of caffeine was added to the intake of theobromine as such, to facilitate comparison of the
total exposure with a reference value derived for theobromine.
2.4.2. Methodology
Dietary exposure to caffeine and theobromine from their use as chemically deﬁned ﬂavouring
substances was estimated by combining food consumption data available within the EFSA
Comprehensive European Food Consumption Database (hereafter Comprehensive Database)4 (EFSA,
2011a) with the maximum permitted levels and/or reported use levels submitted to EFSA by the
ﬂavour industry, as appropriate. In this assessment, a brand loyalty model was chosen. In this model,
it is assumed that a consumer is exposed on a long-term basis to a speciﬁc category of food,
containing the ﬂavouring substance of interest at the maximum use/permitted level. For both caffeine
and theobromine, it was decided that this category of food will be the one resulting in the highest
potential dietary exposure.
4 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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For the remaining categories, normal use levels were applied. This is in line with the added portions
exposure technique (APET) calculations as developed in the guidelines for ﬂavourings (EFSA CEF Panel,
2010).
Dietary exposure to caffeine from all non-ﬂavouring sources (i.e. natural sources, stimulant use)
was estimated by combining food consumption data available within the Comprehensive Database (see
Section 2.4.3) with occurrence data from the literature, as used by the NDA Panel in their assessment
(EFSA NDA Panel, 2015). For theobromine, data reported in the literature was used (Appendix C,
Table C.4). For the systemic exposure to theobromine resulting from caffeine intake, a factor of 0.11
(see Section 2.4.4.2.c) was applied, based on the metabolic conversion of caffeine into theobromine.
Caffeine and theobromine exposure estimates were calculated for each individual in the
Comprehensive Database. Only surveys with collected data for at least 2 days were used. For each
individual, exposure from all identiﬁed food groups was summed up over the entire survey period and
subsequently divided by the number of survey days to derive average daily intakes. Finally, the so
derived estimates were normalised for individual body weight (bw), resulting in an individual average
daily exposure per kg bw for the survey period (absolute intake values in mg of ﬂavouring substance
per day are also provided in Appendix D, Tables D.1 and D.2). High-level exposure was calculated for
only those population groups where the sample size was sufﬁciently large to allow calculation of the
95th percentile (EFSA, 2011b).
Uncertainties on the exposure assessment were identiﬁed and discussed in each relevant section.
2.4.3. EFSA Comprehensive European food consumption database4
Since 2010, the Comprehensive Database has been populated with national data on food consumption
at a detailed level. Competent authorities in the European countries provide EFSA with data on the level of
food consumption by the individual consumer from the most recent national dietary survey in their
country (cf. Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption
Database in Exposure Assessment’) (EFSA, 2011a). New consumption surveys5 recently added in the
Comprehensive database were also taken into account in this assessment (see Appendix B, Table B.1).
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons should be interpreted with caution. Depending on the food
category and the level of detail used for exposure calculations, uncertainties could be introduced owing
to possible subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless,
the EFSA Comprehensive Database represents the best available source of food consumption data
across Europe at present.
Food consumption data from the following population groups: toddlers, children, adolescents, adults
and the elderly were used for the exposure assessment. For the present assessment, food consumption
data were available from 41 different dietary surveys carried out in 23 European countries (Table 4).
Table 4: Population groups considered for the exposure estimates of caffeine and theobromine
Population Age range
Countries with food consumption surveys covering more
than 1 day
Toddlers From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy, Netherlands,
Spain, UK
Children(a) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France,
Germany, Greece, Italy, Latvia, Netherlands, Spain, Sweden, UK
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France,
Germany, Italy, Latvia, Spain, Sweden, UK
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, UK
Elderly From 65 years up to
74 years of age
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Netherlands, Romania, Sweden, UK
Very elderly From 75 years of age and
above
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Netherlands, Romania, Sweden, UK
(a): The terms ‘children’ corresponds, to ‘other children’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive
European Food Consumption Database in Exposure Assessment’ (EFSA, 2011b).
5 Available online: http://www.efsa.europa.eu/en/press/news/150428.htm
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Consumption records were coded according to the FoodEx classiﬁcation system (EFSA, 2011b). For
the purposes of the present assessment, nomenclature from the FoodEx classiﬁcation system was
linked to the Food Categorisation System (FCS) as presented in Annex III of Reg. (EC) 1565/2000 (see
Appendix C, Table C.3).
2.4.4. Food categories and concentration data considered for the exposure
assessment
2.4.4.1. Caffeine
a) Levels of caffeine when used as chemically deﬁned ﬂavouring substance
Use and use levels were provided to EFSA by the ﬂavour industry (Flavour Industry, 2010) and are
detailed below (see Table 5 and Appendix C, Table C.2).
Use and use levels were provided for ﬁve categories; however, only four food categories were
included in the exposure assessment. The use of caffeine in the food category alcoholic beverages is
not authorised and was therefore not taken into account in the present assessment. This may result in
an underestimation of the exposure.
The matching food categories were selected from the EFSA Comprehensive Database, at the most
detailed level possible (up to FoodEx Level 4) (EFSA, 2011b) (see Appendix C, Table C.3).
In order to take brand loyalty into account, it was assumed that a consumer is exposed, on a long-
term basis, to caffeine present at the maximum reported use level in the food category resulting in the
highest potential dietary exposure (i.e. cola beverages) and exposed at normal reported use levels for
the remaining food categories. However, the maximum reported use level for caffeine in cola beverages
exceeded the maximum permitted level (MPL), which constitutes a non-compliance, and therefore, in
this case, the MPL was used instead. This may result in an underestimation of the exposure.
b) Natural and non-ﬂavouring caffeine concentrations in food and beverages
For the purposes of assessing intake from all sources, additional data on non-ﬂavour use (e.g.
stimulant use) and natural occurrence of caffeine was used. For caffeine, this data – taken from the
Table 5: Caffeine use and use levels reported by the ﬂavour industry, maximum permitted levels
(MPLs) and levels used in the exposure assessment (mg/kg or mg/L)
Food category(a) MPL(b)
Use levels provided by
the Flavour Industry
Level used in
the exposure
assessment
(c) Notes
Normal Maximum
(mg/kg or mg/L)
1. Dairy products 70 20 70 20 Only ‘ﬂavoured milk products’ were
considered
3. Edible ices 70 20 70 20 Only ‘milk and non-milk based ice-
creams’ were considered
5. Confectionary 100 25 100 25 Since cocoa is a natural source of
caffeine, only the category of non-
chocolate confectionery was
considered.
14.1 Non-alcoholic
beverages
150 100 175 150 Only ‘caffeinated cola drinks’ were
considered
14.2 Alcoholic
beverages
– 25 100 – Unauthorised use2 and not taken
into account
(a): According to Annex III of Reg. (EC) 1565/20003.
(b): Set by Reg. (EC) 1334/20086.
(c): Assumption that the consumer is loyal to non-alcoholic beverages.
6 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
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literature – is the same as used by the NDA Panel in their assessment of caffeine (EFSA NDA Panel,
2015) (see Table 6).
The concentration data reported by the NDA Panel for the above four food groups was used to
derive exposure estimates from natural and non-ﬂavouring sources. The use of caffeine in energy
drinks, in excess of MPLs for ﬂavouring use6, is permitted for purposes other than imparting ﬂavour.
For these high use levels, speciﬁc labelling requirements are included in the legislation.7 Therefore,
caffeine from energy drinks was included in the exposure assessment from all sources, which was
reported in excess of the applicable MPL for ﬂavouring use, in this assessment scenario, but it was not
included in the exposure assessment for use as a ﬂavouring substance.
The matching food categories were selected from the EFSA Comprehensive Database, at the most
detailed level possible (up to FoodEx Level 4) (EFSA, 2011b) (see Appendix C, Table C.3).
2.4.4.2. Theobromine
a) Levels of theobromine when used as chemically deﬁned ﬂavouring substance
Use and use levels were provided to EFSA by the ﬂavour industry (Flavour Industry, 2010) and are
detailed below.
According to the ﬂavour industry, theobromine is added for ﬂavouring purposes in non-alcoholic
beverages and dairy products (Flavour Industry, 2010) (see Table 7 and Appendix C, Table C.2).
Table 6: Natural and non-ﬂavour caffeine concentrations (mg/kg or mg/L) in food and beverages,
considered in the assessment of caffeine from all sources
Food groups Subgroups
Used in the intake assessment
(mg/kg or mg/L)(a)
Chocolate Chocolate bar 111
Milk chocolate 168
Chocolate snacks
Cocoa beverage-based on cocoa powder
Cocoa beverage-based on cocoa-beverage preparation
powder
42
Dark chocolate 525
Coffee Coffee drink 445
Cappuccino 273
Espresso coffee 1,340
Decaffeinated and imitates 21
Instant coffee, ready to drink 445
Tea Black tea 220
Green tea 151
Tea (unspeciﬁed) 165
Tea, decaffeinated 25
Beverages ‘Energy drinks’ 320
(a): See opinion of the NDA Panel for full details and considerations (EFSA NDA Panel, 2015).
7 Regulation (EU) No 1169/2011 of the European Parliament and of the Council on the provision of food information to
consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council,
and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive
2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission
Regulation (EC) No 608/2004.
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As for caffeine, a brand loyal exposure assessment method (see Section 2.4.4.1.a) was followed,
whereby it was assumed that a consumer is exposed long term to theobromine present at the
maximum reported use in the food category resulting in the highest potential dietary exposure at
the individual level (i.e. non-alcoholic beverages) and exposed at reported normal use levels for the
remaining food category.
The matching food categories were selected from the EFSA Comprehensive Database, at the most
detailed level possible (up to FoodEx Level 4) (EFSA, 2011b) (see Appendix C, Table C.3).
b) Natural and non-ﬂavouring theobromine concentrations in food and beverages
For the purposes of assessing exposure from all sources, additional data on non-ﬂavour use (e.g.
stimulant use) and natural occurrence of theobromine was used. These data was derived from the
literature (see Appendix C, Table C.4 for further details). The average across all reported values was
typically used (see Table 8); however, the Panel noted that the range of theobromine concentrations in
the various food matrices was highly variable and therefore the magnitude and direction of the
uncertainty associated with the estimate could not be determined in this case. Therefore, this
assessment only presents a snapshot of exposure.
No speciﬁc occurrence levels for theobromine in energy drinks were reported by industry. However,
to stay in line with the approach followed for the assessment of caffeine from all sources, theobromine
from energy drinks was included in this scenario to cover uses other than for ﬂavouring purposes.
Therefore, in line with the approach followed for caffeine, theobromine from energy drinks was not
included in the exposure assessment for use as a ﬂavouring substance (e.g. stimulant use as a
ﬂavouring substance).
Table 7: Theobromine use and use levels reported by industry, maximum permitted levels (MPLs)
and levels used in the exposure assessment
Food category(a) MPL(b)
Use levels provided by
the Flavour Industry
Level used in the
exposure
assessment(c) NotesNormal Maximum
(mg/kg or mg/L)
1. Dairy products 70 20 70 20 Only ‘ﬂavoured milk products’
were considered
14.1 Non-alcoholic
beverages
100 75 100 100 Only ‘soft drinks with bitter
principle’ and ‘soft drinks mixed
ﬂavours’ were considered
(a): According to Annex III of Reg. (EC) 1565/20003.
(b): Set by Reg. (EC) 1334/20086.
(c): Assumption that the consumer is loyal to non-alcoholic beverages.
Table 8: Natural and non-ﬂavouring theobromine concentrations (mg/kg or mg/L) in food and
beverages, considered in the assessment of theobromine from all sources
Food groups Subgroups
Used in the intake assessment
(mg/kg or mg/L)
Cocoa powder 22,000
Chocolate Chocolate bar 1,400
Milk chocolate
Chocolate snacks
Cocoa beverage-based on cocoa powder 370
Cocoa beverage-based on cocoa-beverage preparation
powder
93
Dark chocolate 5,500
Tea Black tea 26
Green tea 45
Tea (unspeciﬁed) 40
Beverages ‘Energy drinks’ 100
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c) Systemic sources of theobromine
An additional source of exposure to theobromine is consumption of caffeine, as approximately 11%
of a dose of caffeine is converted to theobromine after ingestion (see Section 2.5). Therefore, to
account for this systemic exposure to theobromine, caffeine values (see Sections 2.4.4.1.a and b)
were converted into theobromine via application of a conversion factor of 0.11 and included in the
assessment to theobromine, to cover combined exposure.
2.4.5. Exposure estimates
2.4.5.1. Caffeine
a) From dietary sources where caffeine is added as a chemically deﬁned ﬂavouring substance
Daily exposure to caffeine added as a chemically deﬁned ﬂavouring substance in food ranged from
0 to 2.3 mg/kg bw per day across all population groups (see Table 9 and Appendix D, Table D.1).
Cola beverages were found to be by far the main contributor to the exposure to caffeine used as a
chemically deﬁned ﬂavouring substance (see Appendix D, Table D.1 and Appendix E, Table E.1).
b) From all dietary sources
Daily exposure to caffeine from all sources in food ranged from 0 to 10 mg/kg bw across all
population groups (see Table 10, Appendix D, Tables D.1 and D.3).
Table E.1, Appendix E provides an overview of the food sources contributing to daily caffeine
exposure for each survey and age group.
The CEF Panel noted that the outcome of the exposure estimate of caffeine from all dietary sources
(including sources where caffeine is added as a ﬂavouring substance) is in line with the one estimated
by the NDA Panel where only the major dietary sources of caffeine were taken into consideration.
Table 9: Summary of dietary exposure to caffeine from its use as chemically deﬁned ﬂavouring
substance, in six population groups (minimum–maximum across the dietary surveys in mg/kg
bw per day)
Exposure from ﬂavouring use (mg/kg bw per day)(a)
Toddlers Children Adolescents Adults The elderly Very elderly
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(65–74
years)
(> 75 years)
Mean 0–1.0 0–0.5 0–0.6 0–0.4 0–0.1 0
95th percentile –(b) 0–2.2 0–2.3 0–1.7 0–0.4 0–0.3
bw: body weight.
(a): Based on the data described in Section 2.4.4.1.a.
(b): The data were insufﬁcient to reliably calculate this ﬁgure.
Table 10: Summary of dietary exposure to caffeine from all sources, in six population groups
(minimum–maximum across the dietary surveys in mg/kg bw per day)
Exposure from all dietary sources (mg/kg bw per day)(a)
Toddlers Children Adolescents Adults The elderly Very elderly
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(65–74
years)
(> 75
years)
Mean 0–1.5 0.2–2.0 0.5–1.4 0.5–4.3 0.3–4.9 0.3–6.0
95th percentile 0.1–3.5 1.5–4.5 1.5–4.3 1.6–10 1.5–10 2.3–6.3
bw: body weight.
(a): Based on the data described in Sections 2.4.4.1.a and b.
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2.4.5.2. Theobromine
a) From dietary sources where theobromine is added as a chemically deﬁned ﬂavouring substance
Daily exposure to theobromine added as a chemically deﬁned ﬂavouring substance in food,
excluding systemic exposure from caffeine, ranged from 0 to 0.4 mg/kg bw, across all population
groups (see Table 11 and Appendix D, Table D.2). When including systemic exposure to theobromine
from internal conversion of caffeine into theobromine, exposure ranged from 0 to 0.5 mg/kg bw per
day across all population groups (see Table 11).
b) From all dietary sources
Daily exposure to theobromine from all sources in food, excluding systemic exposure from caffeine,
ranged from 0.1 to 7.1 mg/kg bw across all population groups (see Table 12, Appendix D, Tables D.2
and D.4). When including systemic exposure to theobromine from internal conversion of caffeine into
theobromine, exposure ranged from 0.1 to 7.4 mg/kg bw across all population groups (see Table 12).
Table E.2, Appendix E provides an overview of the food sources contributing to daily caffeine intake
for each survey and age group.
2.5. Absorption, distribution, metabolism and elimination (Appendix F)
In humans, caffeine is rapidly and completely absorbed after oral intake. It is metabolised by the liver
to a complex set of metabolites, including theobromine and theophylline, by cytochromes (CYP) 1A2 and
3A4, as well as xanthine oxidase and N-acetyltransferase (Lelo et al., 1986a,b). Approximately 11% of a
dose of caffeine is converted to theobromine according to pharmacokinetic studies in six human
volunteers who were dosed with equimolar doses of caffeine (270 mg), as well as its mono-demethylated
Table 11: Summary of dietary exposure to theobromine from use as chemically deﬁned ﬂavouring
substance, in six population groups (minimum–maximum across the dietary surveys in
mg/kg bw per day)
Toddlers Children Adolescents Adults The elderly Very elderly
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(65–74
years)
(> 75 years)
Exposure from ﬂavouring use (excluding systemic exposure from caffeine) (mg/kg bw per day)(a)
Mean 0–0.1 0–0.1 0–0 0–0 0–0 0–0
95th percentile 0–0.3 0–0.4 0–0.1 0–0.1 0–0.1 0–0.1
Exposure from ﬂavouring use (including systemic exposure from caffeine) (mg/kg bw per day)(b)
Mean 0–0.2 0–0.1 0–0.1 0–0.1 0–0 0–0
95th percentile – 0–0.5 0–0.2 0–0.2 0–0.1 0–0.1
bw: body weight.
(a): Based on the data described in Section 2.4.4.2.a.
(b): Based on the data described in Sections 2.4.4.2.a and c.
Table 12: Summary of dietary exposure to theobromine from all sources, in six population groups
(minimum–maximum across the dietary surveys in mg/kg bw per day)
Toddlers Children Adolescents Adults The elderly Very elderly
(12–35
months)
(3–9
years)
(10–17
years)
(18–64
years)
(65–74
years)
(> 75 years)
Exposure from all sources (excluding systemic exposure from caffeine) (mg/kg bw per day)(a)
Mean 0.1–2.9 0.5–2.3 0.3–1.5 0.2–0.7 0.1–0.5 0.1–0.6
95th percentile 0.3–4.9 2–7.1 1.4–6.5 0.8–2.6 0.4–1.4 0.6–1.6
Exposure from all sources (including systemic exposure from caffeine) (mg/kg bw per day)(b)
Mean 0.1–3.1 0.6–2.4 0.4–1.6 0.3–1.1 0.1–0.9 0.2–1.2
95th percentile 0.3–5.1 2.1–7.4 1.5–6.9 1.1–2.9 0.6–2.1 –1.9
bw: body weight.
(a): Based on the data described in Section 2.4.4.2.a and b.
(b): Based on the data described in Section 2.4.4.2.a, b and c.
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metabolites theobromine, theophylline and paraxanthine (250 mg). For each of these compounds and
each volunteer, the pharmacokinetics based on their plasma levels were determined. The mean fractional
conversion of caffeine to paraxanthine, theobromine and theophylline was 80  21%, 10.8  2.4% and
3.7  1.3%, respectively. This is supported by a pharmacokinetically less extensive study in 10
volunteers (Rodopoulos and Norman, 1996).
Caffeine has a short plasma half-life of 4 h (range 3–10 h). The metabolites are readily excreted by
the kidney and are not chemically reactive.
For theobromine, the human data are more limited. Also, in this case, uptake is virtually complete,
and its metabolism results mainly in the same metabolites as caffeine, which are excreted in urine. The
plasma half-life of elimination is somewhat longer and ranges from 7 to 12 h. Also, for theobromine
the metabolites are not chemically reactive. A more detailed description of the metabolism is given in
Appendix F.
2.6. Genotoxicity data
2.6.1. Caffeine
A large number of studies is published on caffeine and its potential genotoxic (mutagenic and
clastogenic) effects alone or in combination with physical and chemical genotoxic agents.
Genotoxicity of caffeine has been evaluated by different international expert groups and Regulatory
Agencies such as IARC (1991), OECD (2002) and by FDA (2011). A comprehensive review is also
available (D’Ambrosio, 1994).
IARC (1991) reported that caffeine affects photoreactivation, excision repair and post-replication
repair (IARC, 1991). The antagonistic effect of caffeine on mutations induced by UV light has been
explained on the basis of inhibition of an error-prone, post-replicative and recombination repair
process. Caffeine can modulate the effects of various xenobiotics by acting on: (i) cytochrome P450;
(ii) cAMP metabolism: (iii) DNA metabolism and repair, chromatin structure and function, (iv)
nucleotide pools, (v) cell cycle checkpoints. These observations were conﬁrmed and extended by
additional studies (Sarkaria et al., 1999; Asaad et al., 2000; Jirmanova et al., 2005; Bode and Dong,
2007; Gabrielli et al., 2007; Tichy et al., 2011; Hatzi et al., 2015).
In the evaluation by IARC (1991), it was concluded that ‘although it has been suggested that
caffeine may induce gene mutations in mammals and man, direct evidence in vivo is limited and the
indirect evidence is largely based on extrapolation from results in lower organisms in which there is no
doubt about the mutagenic action of caffeine, and from cultured mammalian cells, in which caffeine is
clastogenic at high concentrations’. In the comprehensive review by D’Ambrosio (1994), it was
concluded that ‘It is difﬁcult to implicate caffeine, even at the highest levels of dietary consumption, as
a genotoxin to humans’. In the evaluation of OECD (2002), it is reported that, generally gene mutation
assays in bacteria and mammalian cells were negative and that chromosomal aberrations in vitro were
observed only at high concentrations above the recommended levels (> 10 mM). Most of the in vivo
studies resulted negative for gene mutation and chromosomal damage except for a few positive
results obtained for induction of sister chromatid exchanges (SCE’s) whose toxicological relevance was
considered questionable. In this report, it is concluded that, ‘under exposure relevant conditions there
are no indications of genotoxicity of caffeine’ (OECD, 2002).
In the present evaluation, only well-documented studies, relevant for risk assessment (from 1965
up to December 2016) have been evaluated, even though not all of them are in compliance with Good
Laboratory Practice (GLP) and OECD guidelines.
Caffeine has been shown to be consistently negative for the induction of gene mutation in
adequately conducted Salmonella typhimurium his reversion mutation assays (McCann et al., 1975;
Dunkel et al., 1985; Mortelmans et al., 1986; Prival et al., 1991) and in mammalian cells in vitro
(Amacher and Zelljadt, 1984; Clive et al., 1990; Ogawa et al., 2009). Positive results observed in the
mouse lymphoma tk/ mutation assay turned out to be the result of clastogenic events (Clive et al.,
1990; Ogawa et al., 2009). Caffeine did not show reactivity with DNA in Syrian hamster embryo cells
in vitro, as evidenced by the absence of DNA strand breakage and unscheduled DNA synthesis (Casto
et al., 1976).
In the in vitro chromosomal aberration assay, caffeine proved to be a clastogenic compound although
at concentrations close or exceeding 1 mM equal to 195 lg/mL (Kuhlmann et al., 1968; Ishidate et al.,
1984; Wakata and Sasaki, 1987). Induction of chromosomal damage (mainly chromatid breaks) appears
to be generated during S phase only, as reported by Kuhlmann et al. (1968). The S-dependent
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mechanism of induction of chromosomal aberrations has been proved also in different studies performed
at 37°C, the physiological temperature of mammalian cell growth (Kihlman, 1955, 1961; Scott and
Evans, 1964; Kihlman and Odmark, 1965). When the temperature was lowered, the S-dependent
mechanism of chromosomal aberration formation decreased and, at temperatures between 30°C and
15°C, it was replaced by an S-independent mechanism as that observed in plants (Kihlman et al., 1971a,
b). These observations indicate that under physiological conditions caffeine may interfere with replicative
DNA synthesis in mammalian cells determining marked increases of replication units through activation
of new origins of replication (Lehmann, 1972; Tatsumi and Strauss, 1979; Painter, 1980; Schn€os and
Inman, 1982; Barone and Grice, 1990) and that the observed effects on the origin of DNA replication
(replicons) are responsible for the S-dependent production of chromosomal aberrations at
concentrations close to or exceeding 1 mM.
In a large number of in vivo genotoxicity tests (micronuclei, SCE’s, chromosome aberrations
aneuploidy, dominant lethal), both at somatic and germ cell levels, caffeine gave negative results,
although few positive results were observed in some studies (see also references in D’Ambrosio
(1994), IARC (1991), OECD (2002) and by FDA (2011)). Signiﬁcant induction of SCE’s, chromosome
aberrations and micronuclei were observed following in vivo treatment of Chinese hamsters and mice
(Basler et al., 1979; Aeschbacher et al., 1986; Haynes et al., 1996; Choudhury and Palo, 2004).
However, these increases were observed only at the highest dose levels and were generally small in
quantitative terms. Furthermore, in the study by Choudhury and Palo (2004) where micronuclei and
chromosome aberrations were evaluated in bone marrow cells following the same treatment regime,
only chromosome aberrations turned out to be signiﬁcantly increased. Inconsistency between
cytogenetic endpoints was also noted. Under these conditions, inhibition of cell cycle checkpoints and
DNA repair mechanisms which induce both decrease of DNA repair capacities and apoptosis could
explain the clastogenic effect of caffeine observed at high concentrations in vitro and in vivo by
indirect mechanisms with possible threshold.
On this basis, the Panel considered that caffeine is rapidly metabolised in most mammals including
human and that only very high doses of 100 mg/kg bw or higher in animal studies (equivalent to
about 6,000 mg/person per day) resulted in chromosomal damage. This ﬁnding was consistent with
negative results (no increase in the frequency of chromosomal damage) observed by Weinstein et al.
(1972) in lymphocytes of human volunteers exposed in vivo for 4 weeks to 800 mg of caffeine per day
(equal to about 13 mg/kg bw); the highest concentrations of caffeine in plasma was 30 lg/mL.
Overall, the Panel considered caffeine not to be of concern for genotoxicity when used as ﬂavouring
substance.
2.6.2. Theobromine
Since theobromine is one of the metabolites of caffeine, the Panel considered that the conclusion
on caffeine is valid also for theobromine.
2.7. Toxicity data
2.7.1. Caffeine
For the safety assessment of caffeine a very broad human database is available, which eliminates
the need for animal data. The (clinical) pharmacology of caffeine has been extensively studied. Its
favourable central nervous system (CNS) effects (see e.g. (Fredholm et al., 1999; Fredholm, 2011;
Winston et al., 2005) for reviews) are the reason for its wide consumption in e.g. coffee and ‘energy
drinks’. Major effects are CNS stimulation, diuresis, stimulation of cardiac muscle and relaxation of
smooth muscle. Caffeine is registered as a medicine for various indications, including treatment of
apnoea in prematurely born babies (EMEA, 2009; EMA 2015).
The main mechanism of action of caffeine is antagonism of the adenosine A1 and A2 receptors; at
increased dose levels it inhibits phosphodiesterases. Side effects in humans, occurring at higher doses
per day (50–250 mg), are mostly related to the pharmacological actions of caffeine. Beaudoin and
Graham (2011) discussed the epidemiological evidence of effects of caffeine and coffee on several
human health parameters. These authors claim that caffeine intakes are several orders of magnitude
above the proposed levels of its intake as a food additive and therefore the use of caffeine for the
latter speciﬁc purpose does not raise safety concerns (Beaudoin and Graham, 2011).
The safety of caffeine from various dietary sources has been evaluated by the SCF in 1999 and
2003 (see Appendix H) which established a safety threshold of up to 300 mg/day for healthy adults.
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The SCF further concluded that: ‘For children who do not normally consume much tea or coffee, and
who might substitute ‘energy’ drinks for cola or other soft drinks, consumption of ‘energy’ drinks might
represent an increase in daily caffeine exposure compared with their previous intake. The Committee
considered that this could result in transient behavioural changes, such as increased arousal, irritability,
nervousness or anxiety. Risk assessment of caffeine in relation to pregnancy is more difﬁcult. While
intakes up to 300 mg/day appear to be safe, the question of possible effects on pregnancy and the
offspring at regular intakes above 300 mg/day remains open. This suggests that moderation of
caffeine intake, from whatever source, is advisable during pregnancy’ (SCF, 2003).
The SCF evaluation was supported by the critical assessment of Nawrot et al. (2003), who
concluded that below 400 mg/day there are no adverse effects to be expected in the general healthy
population; for pregnancy a threshold of 300 mg/person per day was recommended at that time, and
for children an exposure less than 2.5 mg/kg per day was advised. A recent review of Heckman et al.
(2010) supports this analysis. Schaefer, who also evaluated the use of caffeine and coffee during
pregnancy, concluded that no problem is raised for consumption of ‘normal amounts of caffeine and
theobromine in pregnancy, which correspond to three cups of normal strength coffee with 50–100 mg
of caffeine, or equivalent amounts of other caffeine-containing drinks’ (Schaefer, 2001).
The EFSA NDA Panel has recently evaluated the safety of caffeine from all dietary sources and
came to the following conclusions (EFSA NDA Panel, 2015):
• Caffeine intake from all sources up to 400 mg/day (about 5.7 mg/kg bw per day) does not
raise safety concerns for adults in the general population, except pregnant women.
• Caffeine intake from all sources up to 200 mg/day (about 3 mg/kg bw per day) by pregnant or
lactating women in the general population does not raise safety concerns for the fetus or
breast-fed baby, respectively
• The NDA Panel considered that caffeine intake of no concern derived for acute consumption in
adults (3 mg/kg bw per day) may serve as a basis to derive daily caffeine intakes of no
concern for children and adolescents.
In line with the outcome of the NDA Panel, establishing a no concern level for caffeine of 5.7 mg/bw
per day for adults except pregnant/lactating women and 3 mg/kg bw per day for children, adolescents,
pregnant and lactating women, the CEF Panel decided to apply these caffeine no concern levels as
reference levels for the safety evaluation of caffeine when used as a ﬂavouring substance.
2.7.2. Theobromine
The pharmacology of theobromine has been reviewed by Smit (Smit, 2011). Its major
pharmacological effects in humans include diuresis, relaxation of the smooth muscle, myocardial
stimulation and vasodilatation. Unlike caffeine, theobromine is a very mild stimulant of the CNS,
showing a much lower afﬁnity for most adenosine receptors than caffeine (Baggott et al., 2013;
Judelson et al., 2013). This might explain why theobromine is often regarded as an inert molecule with
respect to its effects on the CNS. Theobromine has been reported to be 2–3 times less active than
caffeine as adenosine A1 receptor antagonist, and at least 10 times less active than caffeine as A2
receptor antagonist. Overall, the pharmacological effects of caffeine and theobromine overlap, but
these substances show differences in relative potency with respect to their effects on e.g. the CNS, the
kidneys or the heart (Tarka, 1982).
The safety of theobromine as undesirable substance in animal feed was evaluated by the EFSA
CONTAM Panel (EFSA, 2008). The Panel concluded that, although theobromine can affect the health of
domestic animals above certain exposures, it is not expected to affect humans who consume the
animal products thereof (see Appendix H).
The CONTAM Panel concluded that target organs of theobromine toxicity in rodents are the testes
(Sertoli cells) and the thymus. Tarka et al. (1979) conducted a 28-day study on the effects of
theobromine incorporated to food in rats, mice and hamsters. Total body and organ weights, as well
as limited organ histopathology, were assessed. Rats treated with the lowest dose of theobromine
(94 mg/kg bw per day for males and 110 mg/kg bw per day for females), (0.2% in the diet) already
showed a lower thymus weight than controls (40% in females and 48% in males). No
histopathological changes were observed at that level. At threefold higher exposures (0.6% in the
diet), microscopy showed pronounced histopathological changes. This atrophic effect on the thymus
appears similar to that observed with caffeine: at 185 mg caffeine/kg bw per day by gavage for
14 days in adult rats a decrease of about 60% in thymus weight resulted. No information on
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histopathology is available from that study (Peters and Boyd, 1967). Mice and hamsters were more
resistant to theobromine. In mice, testicular toxicity appeared at doses of 1,800 mg/kg bw per day of
theobromine (1.2% in the diet) and was accompanied by histopathological changes and high mortality.
In the hamster, no such toxicity was observed even at the highest dose, 1,027 mg/kg bw per day
(1.0% in the diet). In rats fed theobromine in the diet for 49 days, the no observed adverse effect
level (NOAEL) for testicular toxicity was identiﬁed at 88 mg/kg bw per day (Tarka et al., 1981). One
testis was surgically removed after those 49 days (unilateral orchiectomy), and subsequently, the rats
had a recovery period of 49 days (without theobromine in the food). At the 88 mg/kg bw per day
initial dose (during the ﬁrst 49 days), again no damage was observed when the remaining testis was
analysed after that recovery period. However, at the two higher initial exposure levels (244 and
334 mg/kg bw per day), pronounced and irreversible toxicity was observed. In rats and rabbits, the
NOAEL for delay in skeletal development of the off-spring was 48 and 21 mg/kg bw per day,
respectively (Tarka et al., 1986a,b).
The studies on reproduction and developmental toxicity in various animal species have been
extensively reviewed by Tarka (2010). Based on an in-depth safety assessment of all available data on
cocoa powder and theobromine, Tarka (2010) concluded that the data support a NOAEL for
theobromine of about 50 mg/kg bw per day in animals. Similar developmental effects have been
described in rodents for caffeine after gavage of caffeine, with a developmental NOAEL of
approximately 30 mg/kg per day and a teratological NOAEL of 40–100 mg/kg per day (see Nehlig and
Debry, 1994; OECD, 2002; and Brent et al., 2011, for reviews). The CEF Panel noted that the issue of
developmental toxicity of caffeine in animals was considered by the NDA Panel (p. 14 of the NDA
report). However, the NDA Panel derived the level that does not raise a safety concern for pregnant
women (i.e. 200 mg/day) from the available information from epidemiological studies (p. 63–67 and p.
70 of the NDA report). Thus, when setting a reference level for theobromine based on the no concern
level derived for caffeine (see below), the CEF Panel implicitly took into account any possible
developmental effects of caffeine and theobromine.
Unlike for caffeine, no speciﬁc toxicological information on the safety of long-term exposure to
theobromine in humans is available.
In a randomised, double-blind, placebo-controlled human intervention study with a within-subjects
Williams design, the effects of single oral doses of theobromine (250, 500 and 1,000 mg) on mood,
cognitive performance, blood pressure and heart rate were assessed in 84 healthy volunteers using
caffeine (200 mg) as positive control and placebo as neutral control (Baggott et al., 2013). The most
commonly reported adverse effect was headache, which occurred 13 times, nine of which with the
1,000 mg theobromine dose. The second most commonly reported adverse effect was nausea, which
occurred eight times, six of which with the 1,000 mg theobromine dose and two with caffeine. Heart
rate decreased after ingestion of placebo or theobromine but the decrease was slightly less in the 500
and 1,000 mg theobromine groups than in the placebo group. The difference with the decrease in the
placebo group was small (3.5 or 4.9 beats per minute, respectively). No statistically signiﬁcant
difference was observed in heart rate between placebo and the 250 mg theobromine group.
Theobromine had no inﬂuence on blood pressure at any of the dose levels studied. For a single oral
dose, the level of 250 mg/person could be considered as a NOAEL for theobromine in this study.
Only two human studies were identiﬁed in which theobromine was consumed daily for longer
periods of time.
In a double-blind, placebo-controlled, cross-over intervention study in healthy volunteers (n = 42),
each subject consumed a ﬂavanol-rich cocoa drink naturally containing 106 mg of theobromine, a
theobromine-enriched cocoa drink containing 979 mg theobromine and placebo for 3 weeks each,
separated by a 2-week wash-out period (Van den Bogaard et al., 2010). The daily single dose was
administered on an empty stomach in the morning, 1 h before breakfast. Haemodynamic
measurements were taken after an overnight fast at the beginning of each intervention period and
after consuming the last test drink at the end of each intervention period. The 106 mg theobromine
dose had no effects on blood pressure. The 979 mg dose increased 24-h ambulatory systolic blood
pressure (3.2  1.1 mm Hg; mean  SE; compared to placebo) while lowering central systolic blood
pressure (4.3  1.4 mm Hg, also compared to placebo), whereas peripheral systolic blood pressure
was unaffected. A signiﬁcant increase in 24-h ambulatory systolic blood pressure was only observed
within the 2 h following the consumption of the test drink. A frequent side effect was laxation, which
occurred in 10 out of 42 volunteers at the 979 mg theobromine dose. Two volunteers withdrew at that
dose because of nausea (n = 1) and headache (n = 1), which rapidly disappeared upon withdrawal.
This study shows that most healthy volunteers can tolerate daily oral doses of theobromine as high as
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979 mg (14.0 mg/kg bw) for 3 weeks, although such doses of theobromine have side effects. Daily
doses of 106 mg/day (approx. 1.5 mg/kg bw per day) had no such side effects and were well
tolerated. The Panel notes, however, that this study does not provide information about the long-term
health effects of chronic exposure to theobromine.
Another clinical trial was reported by Neuﬁngerl et al. (2013). In this double-blind, randomised,
placebo-controlled, full factorial parallel study, volunteers were assigned, after a 2-week run-in period,
to one of four groups (all groups n = 38, 50% females) each consuming daily, for 4 weeks, a 200 mL
chocolate-ﬂavoured acidiﬁed milk drink containing one of the following: (1) cocoa naturally providing
150 mg theobromine (2.1 mg/kg bw); (2) 850 mg of pure theobromine (12.1 mg/kg bw); (3) cocoa
plus added theobromine, with a total theobromine content of 1,000 mg (14.2 mg/kg bw); (4) placebo,
containing no cocoa powder or added theobromine. The test drink was consumed in the morning, 1 h
before breakfast. Blood lipids, apolipoproteins, blood pressure and heart rate were measured at
baseline and at the end of the study. Adverse events were monitored throughout the study period, i.e.
were spontaneously reported by the subjects or noted by the investigator during one of the visits in
the study centre. Theobromine increased HDL-cholesterol and apolipoprotein A-I, while decreasing
apolipoprotein B and LDL-cholesterol. Theobromine had no effect on systolic or diastolic blood pressure
or 24-h heart rate, An acute transient increase in heart rate during the ﬁrst few hours after
consumption of the high (added) theobromine doses (groups 2 and 3) was observed. A total of 18, 43,
57, and 10 adverse effects were reported in groups 1, 2, 3 and 4, respectively. The most commonly
reported adverse effects were nausea, vomiting, headache, and diarrhoea, and all except one were of
mild to moderate intensity and resolved before the end of the study. Adverse events lead to the
premature withdrawal of eight subjects, of which six were in group 3, one in group 2 and one in group
4. One volunteer from group 1 left the study because of ‘personal reasons’. The Panel notes that doses
of 150 mg theobromine/day in cocoa were well tolerated in this study, whereas the number adverse
events increased with (added) theobromine at doses of 850 mg/day and were highest with the highest
total dose of theobromine (1,000 mg/day from cocoa plus added theobromine). The Panel also notes
that, in this study, the intervention lasted 4 weeks only.
In these two clinical trials (Van den Bogaard et al., 2010; Neuﬁngerl et al., 2013), doses of 1.5 and
2.1 mg/kg bw of theobromine were well tolerated when consumed daily in a single dose and in fasting
conditions for 3–4 weeks. However, the Panel decided to use these studies as supportive evidence
rather than to derive a reference dose for the safety assessment of theobromine because the studies
were not designed to assess safety (but rather focus on effects that might reduce the risk of
cardiovascular disease), were of short duration, and do not reﬂect the conditions in which theobromine
is likely to be consumed (spread out throughout the day).
Therefore, for the evaluation of the safety of theobromine as a ﬂavouring substance in food, the
Panel chose to base its assessment on the data on caffeine. To derive a reference dose for
theobromine from the caffeine data, the Panel used the results of pharmacokinetic studies on caffeine
and its metabolites (Lelo et al., 1986a,b). In these studies, six human volunteers were dosed with
equimolar doses of caffeine (270 mg), as well as its mono-demethylated metabolites theobromine,
theophylline and paraxanthine (250 mg). For each of these compounds and each volunteer, the
pharmacokinetics based on their plasma levels were determined. The mean fractional conversion of
caffeine to paraxanthine, theobromine and theophylline was 80  21%, 10.8  2.4% and
3.7  1.3%, respectively. This is supported by a pharmacokinetically less extensive study in 10
volunteers (Rodopoulos and Norman, 1996). Consequential to these studies, the Panel decided to use
this information for the safety assessment of theobromine (i.e. 11% of the oral intake of caffeine is
converted to theobromine within the body) (see Appendix F and Lelo et al., 1986a,b). Caffeine intakes
of no safety concern of 5.7 mg/bw per day for adults except pregnant/lactating women and of 3 mg/kg
bw per day for children, adolescents, pregnant and lactating women (EFSA NDA Panel, 2015) would
hence translate into theobromine exposures of 0.6 mg/kg bw for adults and 0.3 mg/kg bw per day for
children and adolescents, respectively, which in fact represent a systemic exposure to theobromine. The
Panel considered that these exposure levels of theobromine do not raise a safety concern. Thus, the
Panel decided to use them in the current revision of FGE.49.
The Panel considered the following:
• The reference value which is used for the current assessment of theobromine as a chemically
deﬁned ﬂavouring substance is based on the systemic exposure to theobromine after caffeine
intake. However, it does not take into account the food matrix effects, which may decrease the
extent of absorption (see Appendix F).
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• In the clinical studies of 3–4-week duration, no adverse effects were reported at the dose of
1.5–2.1 mg/kg bw per day.
• The use of values of 0.6 and 0.3 mg theobromine/kg bw per day implies that all effects which
led to the derivation of reference levels of 5.7 and 3 mg/kg bw per day for caffeine, are
exclusively due to theobromine, a worst-case assumption for theobromine. However, this is
unlikely because caffeine is pharmacologically more active than theobromine, as indicated by
differences in receptor afﬁnities.
Based on these considerations, the Panel recognised that the values of 0.6 and 0.3 mg/kg bw per
day for theobromine are conservative reference values. While in the clinical studies of 3–4-week
duration no adverse effects were reported at dose levels of 1.5–2.1 mg/kg bw per day, the actual ‘no
adverse effect level’ of theobromine for humans is not known, but it is probably higher. Therefore, the
values of 0.6 and 0.3 mg/kg bw per day could be used as conservative reference points for the safety
evaluation of theobromine when used as ﬂavouring substance. Firm conclusions concerning potential
health risks from total dietary exposure to theobromine can therefore not be drawn, however,
exceedance of the reference value does not necessarily represent a safety concern.
2.7.3. Carcinogenicity studies
IARC evaluated the carcinogenic properties of caffeine and theobromine in 1991. For caffeine, ﬁve
studies in rats were available of which two were negative and the other three were found to be
inadequate for evaluation; the mouse studies were also inadequate. The available epidemiological data
did not show correlation with any tumour. IARC therefore classiﬁed caffeine in Group 3: ‘not
classiﬁable as to its carcinogenicity to humans’ (IARC, 1991).
Many epidemiological investigations on associations between coffee and various cancer sites since
then have been published; a meta-analysis from 2011 of these data concludes that there is no
association; if anything, the analysis suggests that coffee may reduce the total cancer incidence (Yu
et al., 2011). The latter is also mechanistically discussed by Beaudoin and Graham (2011). Earlier, IARC
had classiﬁed ‘coffee’ as 2B (IARC, 1991), based on a signal for bladder cancer, while caffeine as pure
compound was in group 3. The majority of high-quality studies that have subsequently been published,
however, do not show consistent evidence that coffee consumption is associated with bladder cancer.
Very recently, IARC re-evaluated ‘drinking coffee’ as to its carcinogenicity. They concluded that ‘overall
coffee drinking was evaluated as inclassiﬁable (group 3) as to its carcinogenicity to humans’ based on the
extensive epidemiological database available as well as on animal studies (IARC, 2016).
IARC classiﬁed theobromine in Group 3: ‘not classiﬁable as to its carcinogenicity to humans’ because
of lack of data (IARC, 1991). The structurally related theophylline was evaluated in an NTP toxicology
and carcinogenesis study (NTP, 1998). The complete 2 year carcinogenesis studies in rats and mice at
maximum dose levels of 75 mg/kg bw by gavage showed no carcinogenicity of theophylline.
2.8. Safety assessment of caffeine and theobromine added as chemically
deﬁned ﬂavouring substances to food
2.8.1. Caffeine [FL-no: 16.016]
For the evaluation of the present FGE, the most recent assessment on caffeine published by the
NDA Panel was used. According to the NDA opinion, which refers to the major sources of caffeine, an
intake of up to 400 mg/person per day is safe for healthy adults except pregnant and lactating
women. For pregnant and lactating women, an intake of 200 mg/day does not raise safety concerns
for the fetus and breastfed infant. The NDA Panel concluded that an (acute) intake of 3 mg/kg bw per
day may serve as a basis to derive daily caffeine intakes of no concern for children and adolescents
(EFSA NDA Panel, 2015).
Based on the maximum permitted use level6 of 150 mg/kg in non-alcoholic beverages, and normal
use levels of 20 mg/kg in dairy products, 20 mg/kg in edible ices and 25 mg/kg in confectionary,
exposure could be calculated for various age groups for a large number of food surveys covering
various European countries. The mean dietary intakes (ranging from 0 to 1 mg/kg bw per day) and
the 95th percentile exposure estimates (ranging from 0 to 2.3 mg/kg bw per day) to caffeine as a
chemically deﬁned ﬂavouring substance were below the 3.0 mg/kg bw per day level of no concern
applicable to the population aged up to 18 years and the level of 5.7 mg/kg bw per day applicable to
the population above 18 years of age (see Table 9).
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The CEF Panel therefore concluded that caffeine would not be expected to present a safety concern
from its use as ﬂavouring substance at the use levels speciﬁed in Table 5 (see ‘Level used in the
exposure assessment’), as provided by the ﬂavour industry.
The Panel noted that the outcome of the exposure estimate to caffeine from all dietary sources
(including sources where caffeine is added as a chemically deﬁned ﬂavouring substance) is in line with
the one estimated by the NDA Panel where only the major dietary sources of caffeine were taken into
consideration. Cola beverages were found to be by far the main contributor to the exposure to caffeine
used as a chemically deﬁned ﬂavouring substance (Flavour Industry, 2010).
2.8.2. Theobromine [FL-no: 16.032]
Like for caffeine, the Panel decided to not evaluate theobromine through the Procedure but to base
its assessment on the fact that theobromine is a major metabolite of caffeine. Thus, the information
available on the safety of caffeine in the NDA opinion could also be used for the safety assessment of
theobromine. Unlike caffeine, having a broad human database of toxicity studies, no speciﬁc
toxicological information on the safety of long-term theobromine exposure in humans is available. For
the evaluation of theobromine, the Panel decided not to focus on the outcome of the animal studies
available for this substance, but to base its assessment on the human data on caffeine.
To derive a reference value for the safety assessment of theobromine, the Panel used the results of
pharmacokinetic studies on caffeine and its metabolites as described by Lelo et al. (1986a,b), that
indicate that approximately 11% of the oral intake of caffeine is converted to theobromine (see
Appendix F). Since caffeine intake levels of 5.7 mg/kg bw per day for adults except pregnant/lactating
women and 3 mg/kg bw per day for children, adolescents, pregnant and lactating women,
respectively, are not expected to be of safety concern (EFSA NDA Panel, 2015); consequently, for
theobromine intake levels (in fact: systemic exposure levels) of at least 0.6 mg/kg bw for adults except
pregnant/lactating women and 0.3 mg/kg bw per day for children, adolescents, pregnant and lactating
women is also not anticipated to be of safety concern. The Panel noted that caffeine and theobromine
interact with the same receptors and that, therefore, caffeine might modify the toxicity of
theobromine. However, the available data suggest that the 0.6 and 0.3 mg/kg bw per day levels
derived for theobromine from caffeine intake are conservative as outlined in Section 2.7.2.
Exposure of volunteers to theobromine for a duration of 3–4 weeks in valid clinical studies also
indicate that the above reference values are conservative showing no adverse effects at an oral intake
of 1–2 mg/kg bw per day, whereas at the higher dose of 12–15 mg/kg bw per day given as a single
dose on an empty stomach, the side effects were mild. Nevertheless, these are short-term reports,
mostly related to the beneﬁcial effects of the substance rather than to its safety.
Therefore, the levels of 0.6 mg/kg bw per day for adults except pregnant/lactating women and
0.3 mg/kg bw per day for children, adolescents, pregnant and lactating women were used as
reference values for the safety assessment of the ﬂavouring substance theobromine.
Based on the maximum permitted use level6/maximum use level notiﬁed by industry of 100 mg/kg
for non-alcoholic beverages and normal use level of 20 mg/kg for dairy products (see Table 7), the
exposure to theobromine could be calculated for various age groups for a large number of food
surveys in various European countries. The mean dietary intakes of theobromine as a chemically
deﬁned ﬂavouring substance (ranging from 0 to 0.1 mg/kg bw per day) were below the 0.3 mg/kg bw
per day level in all age groups and food surveys (see Table 11). The 95th percentile exposure
estimates to theobromine as a chemically deﬁned ﬂavouring substance (ranging from 0 to 0.4 mg/kg
bw per day) was below the 0.3 mg/kg bw per day level for all age groups except for children from 3
to 10 years old where the 95th percentile exposure estimate rose up to 0.4 mg/kg bw per day.
Also taking into account systemic exposure to theobromine as metabolite of caffeine, mean
exposure across all population groups ranged from 0 to 0.2 mg/kg bw per day and 95th percentile
exposure estimates ranged from 0 to 0.5 mg/kg bw per day (see Table 11). With the exception of
children 3–10 years old (P95 exposure of 0.5 mg/kg bw per day), all exposure levels, resulting from
use of caffeine and theobromine as ﬂavouring substance, were below the extrapolated no concern
level of 0.3 mg/kg bw per day.
The contribution of exposure to theobromine as chemically deﬁned ﬂavouring substance to the
overall exposure to theobromine is negligible.
Considering the conservative nature of the derived reference values for theobromine (0.6 and
0.3 mg/kg bw per day for adults except pregnant/lactating women and children, adolescents pregnant
and lactating women, respectively), the 95th percentile exposure estimates in all age groups and
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dietary surveys are not considered to be of safety concern. The CEF Panel therefore concluded that
theobromine would not be expected to present a safety concern from its use as a chemically deﬁned
ﬂavouring substance at the use levels speciﬁed in Table 7 (see ‘Level used in the exposure
assessment’), as provided by the ﬂavour industry.
The results of the evaluation of caffeine and theobromine are summarised in Appendix G, Table G.1.
3. Conclusions
Following a request from the European Commission, the CEF Panel was asked to deliver scientiﬁc
advice to the Commission on the implications for human health of chemically deﬁned ﬂavouring
substances used in or on foodstuffs in the Member States. In particular, the Panel was requested to
evaluate two ﬂavouring substances in the FGE.49Rev1, using the Procedure as referred to in the
Commission Regulation (EC) No 1565/2000. These two ﬂavouring substances belong to chemical
group 30, Annex I of the Commission Regulation (EC) No 1565/2000 and are both xanthine alkaloids
from the priority list: caffeine [FL-no: 16.016] and theobromine [FL-no: 16.032].
For the evaluation of the present FGE, information from the most recent assessment of caffeine,
published by the NDA Panel is used. Based on this extensive evaluation, and the fact that theobromine
is a metabolite of caffeine, the CEF Panel considered it inappropriate to evaluate caffeine and
theobromine through the Procedure and decided to investigate the safety of both substances based on
their common metabolic pathways and on the safety threshold values for caffeine (5.7 and 3 mg/kg
bw per day for adults except pregnant/lactating women and children/adolescents/pregnant and
lactating women, respectively), derived by the EFSA NDA Panel.
Speciﬁcations
Speciﬁcations including complete purity criteria and identity for the materials of commerce have
been provided and considered adequate.
Use and exposure
The two candidate ﬂavouring substances have been reported to occur naturally in foods such as
coffee, chocolate, tea and cocoa beans as well as in some other plants such as guarana seeds, mate
leaves and yoco bark.
Dietary exposure to caffeine and theobromine from their use as chemically deﬁned ﬂavouring
substances was estimated by combining food consumption data available within the EFSA
Comprehensive European Food Consumption Database4 with the MPLs and/or reported use levels
submitted to EFSA by the ﬂavour industry.
In this assessment, a brand loyalty model was chosen. In this model, it was assumed that a
consumer is exposed on a long-term basis to a speciﬁc category of food, containing the ﬂavouring
substance of interest at the maximum use/permitted level. For both caffeine and theobromine, it was
decided that this category of food will be the one resulting in the highest potential dietary exposure.
For the rest of the categories, normal use levels were applied.
Absorption, distribution, metabolism and elimination
In humans, caffeine is rapidly and completely absorbed after oral intake. It is metabolised by the
liver to a complex set of metabolites, including theobromine (which comprises 11% of a caffeine dose)
and theophylline, by CYP 1A2 and 3A4, as well as xanthine oxidase and N-acetyltransferase. It has a
short plasma half-life of 4 h (range 3–10 h). The metabolites are readily excreted by the kidney and
are not chemically reactive.
For theobromine, the human data are more limited. Also, in this case, uptake is virtually complete,
while its metabolism results mainly in the same metabolites as caffeine, which are excreted in urine.
The plasma half-life of elimination is somewhat longer and ranges from 7 to 12 h. Also for
theobromine, the metabolites are not chemically reactive.
Genotoxicity
Based on the data available on the genotoxic potential of caffeine [FL-no: 16.016] and considering
that theobromine [FL-no: 16.032] is a major metabolite of caffeine, it is concluded that there is no
concern for genotoxicity for both candidate substances.
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Toxicological basis of safety assessment
Caffeine and theobromine have similar pharmacological proﬁles. In 2015, the NDA Panel has
evaluated the safety of caffeine from all dietary sources and came to the following conclusions (EFSA
NDA Panel, 2015):
• Caffeine intake from all sources up to 400 mg/day (5.7 mg/kg bw per day) does not raise
safety concerns for adults in the general population, except pregnant and lactating women.
• Caffeine intake from all sources up to 200 mg/day (about 3 mg/kg bw per day) by pregnant or
lactating women in the general population does not raise safety concerns for the fetus or
breast-fed baby, respectively.
• The NDA Panel concluded that a caffeine intake of no concern derived for acute consumption
in adults (3 mg/kg bw per day) may serve as a basis to derive a daily caffeine intake of no
concern for children and adolescents.
In line with the outcome of the NDA Panel, the CEF Panel decided to apply these levels of no safety
concern, for the evaluation of caffeine when used as a chemically deﬁned ﬂavouring substance.
Unlike caffeine, having a broad database of human toxicity studies, no speciﬁc toxicological information
on the safety of long-term exposure to theobromine in humans is available. For the evaluation of
theobromine, the Panel decided not to focus on the outcome of the animal studies available for this
substance, but to base its assessment on the human data on caffeine. To derive a reference dose for
theobromine from the caffeine data, the Panel used the results of pharmacokinetic studies on caffeine and
its metabolites indicating that approximately 11% of the oral intake of caffeine is converted to
theobromine. Based on the no safety concern level of 5.7 mg/kg bw per day for adults except pregnant/
lactating women and 3 mg/kg bw per day for children, adolescents, pregnant and lactating women
derived by the NDA Panel (EFSA NDA Panel, 2015), a level (in fact: a systemic exposure level) of 0.6 mg/kg
bw for adults except pregnant/lactating women and 0.3 mg/kg bw per day for children, adolescents,
pregnant and lactating women could be anticipated to be of no safety concern for theobromine.
The Panel considered the following:
• The reference value which was used for the current assessment of theobromine as a
chemically deﬁned ﬂavouring substance is based on the systemic exposure to theobromine
after caffeine intake. However, it does not take into account the food matrix effects, which
may decrease the extent of absorption.
• In the clinical studies of 3–4-week duration, no adverse effects were reported at the dose of
1.5–2.1 mg theobromine/kg bw per day.
• The use of values of 0.6 and 0.3 mg theobromine/kg bw per day implies that all effects which
led to the derivation of reference levels of 5.7 and 3 mg/kg bw per day for caffeine, are
exclusively due to theobromine, a worst-case assumption for theobromine. However, this is
unlikely because caffeine is pharmacologically more active than theobromine, as indicated by
differences in receptor afﬁnities.
Based on these considerations, the Panel recognises that the values of 0.6 and 0.3 mg/kg bw per day
for theobromine are conservative reference values. While in the clinical studies of 3–4-week duration, no
adverse effects were reported at the dose levels of 1.5–2.1 mg/kg bw per day, the ‘no adverse effect
level’ of theobromine for humans is not known but it is probably higher. The Panel noted that the most
commonly reported adverse effects were nausea, vomiting, headache, and diarrhoea in doses higher
than 500 mg theobromine consumed. Therefore, the values of 0.6 and 0.3 mg/kg bw per day could be
used as conservative values for the safety evaluation of theobromine when used as ﬂavouring
substance. Firm conclusions concerning potential health risks from total dietary theobromine cannot be
made and exceedance of the reference value does not necessarily represent a safety concern.
Safety assessment of caffeine and theobromine when used as chemically
deﬁned ﬂavouring substances
Dietary exposure to caffeine could be calculated for various age groups for a large number of food
surveys covering various European countries, based on the maximum permitted6 use level available for
the food category resulting in the highest potential dietary exposure (i.e. non-alcoholic beverages) and
normal use levels for the rest of the categories (dairy products, edible ices and confectionary). The
mean and 95th percentile exposure estimates to caffeine as a chemically deﬁned ﬂavouring substance
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were below the 3.0 mg/kg bw per day level of no concern applicable to the population aged up to
18 years and the level of 5.7 mg/kg bw per day applicable to the population above 18 years of age.
The CEF Panel therefore concluded that caffeine would not be expected to present a safety concern
from its use as ﬂavouring substance at the use levels speciﬁed in Table 5 (see ‘Level used in the
exposure assessment’), as provided by the ﬂavour industry.8
The Panel noted that the outcome of the exposure estimate of caffeine from all dietary sources
(including sources where caffeine is added as a ﬂavouring substance) is in line with the one estimated
by the NDA Panel where only the major dietary sources of caffeine were taken into consideration. Cola
beverages were found to be by far the main contributor to the exposure to caffeine used as a
chemically deﬁned ﬂavouring substance.
Dietary exposure to theobromine was calculated for various age groups for a large number of food
surveys covering various European countries, based on the maximum permitted6 use level available for
the food category resulting in the highest potential dietary exposure (i.e. non-alcoholic beverages) and
normal use levels for the rest of the categories (dairy products). The so obtained mean and 95th
percentile exposure estimates were below 0.3 mg/kg bw per day level in all age groups and food
surveys except for children from 3 to 10 years old where the 95th percentile intake level was found to
be 0.4 mg/kg bw per day.
The combined exposure to theobromine from intake of theobromine as such and from intake of
caffeine was also assessed. In this assessment, systemic exposure to theobromine as metabolite of
caffeine was added to the intake of theobromine as such to facilitate comparison of the total exposure
with a reference value derived for theobromine.
The so obtained mean and 95th percentile exposure estimates were below 0.3 mg/kg bw per day
in all age groups and food surveys except for children from 3 to 10 years old where the 95th
percentile intake level rose up to 0.5 mg/kg bw per day.
The contribution of theobromine as chemically deﬁned ﬂavouring substance to the overall exposure
to theobromine was found to be negligible.
Considering the conservative nature of the derived reference values for theobromine (0.6 and
0.3 mg/kg bw per day for adults and children/adolescents/pregnant and lactating women,
respectively), the 95th percentile exposure estimates in all age groups and dietary surveys are not
expected to be of safety concern for its use as ﬂavouring. The CEF Panel therefore concluded that
theobromine would not be expected to present a safety concern from its use as a chemically deﬁned
ﬂavouring substance at the use levels speciﬁed in Table 7 (see ‘Level used in the exposure
assessment’), as provided by the ﬂavour industry.
Conclusion
The Panel concluded that caffeine [FL-no: 16.016] and theobromine [FL-no: 16.032] do not present
a safety concern from their use as chemically deﬁned ﬂavouring substances in food, on the basis of
levels of intake as estimated from the use levels considered in the exposure assessment.
Documentation provided to EFSA
1) EFFA (European Flavour and Fragrance Association), 2002. Letter from EFFA to Dr. Joern Gry,
Danish Veterinary and Food Administration. Dated 31 October 2002. Re.: Second group of
questions. FLAVIS/8.26.
2) EFFA (European Flavour and Fragrance Association), 2004. Intake - Collection and collation
of usage data for ﬂavouring substances. Letter from Dan Dils, EFFA to Torben Hallas-Møller,
EFSA. May 31, 2004.
3) EFFA (European Flavour and Fragrance Association), 2007. E-mail from EFFA to FLAVIS
Secretariat, National Food Institute, Technical University of Denmark. Dated 8 February 2007.
RE: FLAVIS submissions - use levels for Category 14.2 - Alcoholic beverages. FLAVIS/8.70.
4) Flavour Industry, 2010. Unpublished information submitted by Flavour Industry to EFSA and
forwarded to FLAVIS Secretariat. A-49Rev1 [FL-no: 16.016 and 16.032].
5) IOFI (International Organization of the Flavor Industry), 1995. European inquiry on volume
of use.
8 The maximum use level provided by industry for 14.1 non-alcoholic beverages was 175 mg/kg, which exceeds the MPL of
150 mg/kg; however, assuming that ofﬁcial control would remove non-compliant products from the market, the assessment
was based on the MPL and might therefore lead to an underestimate of exposure.
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Abbreviations
7-MX 7-methylxanthine
ADI acceptable daily intake
AFMU 5-acetylamino-6-formylamino-3-methyluracil
APET added portions exposure technique
BW body weight
cAMP cyclic adenosine monophosphate
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CAS Chemical Abstract Service
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CNS central nervous system
CoE Council of Europe
CONTAM EFSA Panel on Contaminants in the Food Chain
CYP cytochrome
EFFA European Flavour and Fragrance Association
FAO Food and Agriculture Organization of the United Nations
FCS Food Categorisation System
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP Good Laboratory Practice
HDL high-density lipoprotein
IARC International Agency for Research on Cancer
ID identity
IOFI International Organization of the Flavour Industry
IR infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
LDL low-density lipoprotein
MPL maximum permitted level
MSDI Maximised Survey-derived Daily Intake
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NOAEL no observed adverse effect level
OECD Organization for Economic Co-operation and Development
SCE sister chromatid exchange
SCF Scientiﬁc Committee on Food
WHO World Health Organization
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Appendix A – Procedure for the safety evaluation
Although for the evaluation of caffeine and theobromine the conventional Procedure as described in
this Appendix has not been used, in various places in the opinion, reference to this Procedure is made.
For sake of clarity, this appendix, in which the Procedure is outlined, has been maintained.
The approach for a safety evaluation of chemically deﬁned ﬂavouring substances as referred to in
Commission Regulation (EC) No 1565/2000, named the ‘Procedure’, is shown in schematic form in
Figure A.1. The Procedure is based on the Opinion of the Scientiﬁc Committee on Food expressed on 2
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of ﬂavourings into three structural classes (I, II and III) for which
thresholds of concern (human exposure thresholds) have been speciﬁed. Exposures below these
thresholds are not considered to present a safety concern.
Class I contains ﬂavourings that have simple chemical structures and efﬁcient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains ﬂavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
ﬂavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest signiﬁcant toxicity (Cramer et al., 1978). The thresholds of concern for these structural
classes of 1,800, 540 or 90 lg/person per day, respectively, are derived from a large database
containing data on subchronic and chronic animal studies (JECFA, 1996).
In Step 1 of the Procedure, the ﬂavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the ﬂavourings be predicted to be metabolised to innocuous products9 (Step 2)?
• Do their exposures exceed the threshold of concern for the structural class (Steps A3 and B3)?
• Are the ﬂavourings or their metabolites endogenous10 (Step A4)?
• Does a NOAEL exist on the ﬂavourings or on structurally related substances (Steps A5 and B4)?
In addition to the data provided for the ﬂavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to ﬂavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on speciﬁc ﬂavourings warranted
such actions.
9 ‘Innocuous metabolic products’: Products that are known or readily predicted to be harmless to humans at the estimated
intakes of the ﬂavouring agent’ (JECFA, 1997).
10 ‘Endogenous substances’: Intermediary metabolites normally present in human tissues and ﬂuids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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Appendix C – Dietary sources and occurrence data
Normal and maximum use levels of the ﬂavouring substances
The ﬂavour industry reports a ‘normal use level’ and a ‘maximum use level’ for each one of the
food categories in which the candidate substances are used (Table C.2). These food categories are
part of the 18 food categories reported in Annex III of Regulation (EC) No 1565/2000 (Table C.1).
According to the ﬂavour industry, the ‘normal use’ is deﬁned as the average of reported usages and
‘maximum use’ is deﬁned as the 95th percentile of reported usages (EFFA, 2002). The normal and
maximum use levels in different food categories have been extrapolated from ﬁgures derived from
12 model ﬂavouring substances (EFFA, 2004).
Table C.1: Food categories according to Commission Regulation (EC) No 1565/2000
Food category Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (including mushrooms & fungi, roots & tubers, pulses and legumes),
and nuts & seeds
05.0 Confectionery
06.0 Cereals and cereal products, including ﬂours & starches from roots & tubers, pulses &
legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and ﬁsh products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (‘soft’) beverages, excluding dairy products
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that could not be placed in
categories 01.0–15.0
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Appendix D – Daily caffeine and theobromine intake from all dietary
sources and by country survey and age class
Table D.1: Daily caffeine intake for all subjects by age class and food group across different dietary
surveys from added ﬂavourings and other sources
Age class Food groups
Mean caffeine intake
95th percentile caffeine
intake(a)
mg per day
mg/kg bw
per day
mg per day
mg/kg bw per
day
Min(b) Max(b) Min(b) Max(b) Min(b) Max(b) Min(b) Max(b)
Toddlers
(12 to < 36
months; 10 surveys)
Cola beverages 0.0 12 0.0 0.8 0.0 0.0 0.0 0.0
Other ﬂavouring sources 0.0 1.4 0.0 0.1 0.3 4.6 0.0 0.3
All ﬂavouring sources 0.0 13 0.0 1.0 0.3 6.6 0.0 0.4
Chocolate 0.3 18 0.0 1.2 0.5 24 0.1 1.8
Coffee 0.0 1.9 0.0 0.2 0.0 0.0 0.0 0.0
Tea 0.0 6.6 0.0 0.5 0.0 43 0.0 3.2
Total intakes(c) 0.4 20 0.0 1.5 0.9 49 0.1 3.5
Other children
(3 to < 10 years;
18 surveys)
Cola beverages 0.0 8.7 0.0 0.4 0.0 38 0.0 2.1
Other ﬂavouring sources 0.1 1.7 0.0 0.1 1.0 6.9 0.0 0.4
All ﬂavouring sources 0.1 9.8 0.0 0.5 1.0 40 0.0 2.2
Chocolate 2.1 22 0.1 0.9 6.5 57 0.4 2.7
Coffee 0.0 10 0.0 0.4 0.0 45 0.0 1.6
Tea 0.0 32 0.0 1.3 0.0 70 0.0 2.8
‘Energy drinks’ 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 3.9 47 0.2 2.0 22 104 1.5 4.5
Adolescents
(10 to < 18 years;
17 surveys)
Cola beverages 0.0 37 0.0 0.6 0.0 149 0.0 2.3
Other ﬂavouring sources 0.1 1.4 0.0 0.0 0.6 5.7 0.0 0.1
All ﬂavouring sources 0.1 37 0.0 0.6 0.6 149 0.0 2.3
Chocolate 2.8 32 0.1 0.6 9.8 130 0.2 2.9
Coffee 0.5 22 0.0 0.4 0.0 134 0.0 2.1
Tea 0.0 36 0.0 0.8 0.0 122 0.0 2.4
‘Energy drinks’(d) 0.0 5.7 0.0 0.1 0.0 40 0.0 0.8
Total intakes 22 79 0.5 1.4 63 226 1.5 4.3
Adults
(18 to < 65 years;
18 surveys)
Cola beverages 0.0 25 0.0 0.4 0.0 112 0.0 1.7
Other ﬂavouring sources 0.1 0.8 0.0 0.0 0.5 4.0 0.0 0.1
All ﬂavouring sources 0.1 25 0.0 0.4 0.7 112 0.0 1.7
Chocolate 1.9 9.5 0.0 0.1 8.4 50 0.1 0.8
Coffee 22 281 0.3 3.7 80 737 1.1 9.7
Tea 0.5 89 0.0 1.2 0.0 247 0.0 3.4
‘Energy drinks’(e) 0.0 4.4 0.0 0.1 0.0 34 0.0 0.4
Total intakes 37 323 0.5 4.3 110 745 1.6 10
Elderly
(65 to < 75 years;
14 surveys)
Cola beverages 0.0 4.8 0.0 0.1 0.0 32 0.0 0.4
Other ﬂavouring sources 0.0 1.1 0.0 0.0 0.3 6.0 0.0 0.1
All ﬂavouring sources 0.0 5.1 0.0 0.1 0.3 32 0.0 0.4
Chocolate 1.0 5.0 0.0 0.1 4.2 30 0.1 0.4
Coffee 19 331 0.3 4.4 94 712 1.4 10
Tea 1.4 124 0.0 1.7 15 297 0.2 4.0
‘Energy drinks’ 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 23 363 0.3 4.9 96 716 1.5 10
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Age class Food groups
Mean caffeine intake
95th percentile caffeine
intake(a)
mg per day
mg/kg bw
per day
mg per day
mg/kg bw per
day
Min(b) Max(b) Min(b) Max(b) Min(b) Max(b) Min(b) Max(b)
Very elderly
(≥ 75 years; 12
surveys)
Cola beverages 0.0 2.6 0.0 0.0 0.0 19 0.0 0.3
Other ﬂavouring sources 0.0 1.0 0.0 0.0 0.3 5.7 0.0 0.1
All ﬂavouring sources 0.1 2.7 0.0 0.0 0.5 19 0.0 0.3
Chocolate 1.5 9.3 0.0 0.1 4.4 37 0.1 0.6
Coffee 17 383 0.2 5.5 134 417 1.8 5.9
Tea 0.8 126 0.0 1.8 48 283 0.7 4.2
‘Energy drinks’ 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 22 417 0.3 6.0 174 456 2.3 6.3
bw: body weight.
(a): The 95th percentile estimates obtained from dietary surveys and age classes with less than 60 subjects may not be
statistically robust (EFSA, 2011b) and were consequently not considered in this table. As a result of this, for some of the age
groups, the intake at the 95th percentile level may be lower than the mean intake (e.g. ‘toddlers, all ﬂavourings sources’).
(b): Ranges of minimum and maximum of mean and 95th percentiles values across the number of individual surveys indicated for
each age class.
(c): ‘Total intakes’ reﬂect the minimum and maximum intakes calculated across the individual surveys for all food categories. N.B.
Total intakes are not derived by summing the values in each column for each age group.
(d): Only one study (the Netherlands) with a sufﬁcient number (≥ 60) of subjects who had consumed ‘energy drinks’ was
available to estimate a statistically robust 95th percentile.
(e): Only two studies (the Netherlands and Ireland) with a sufﬁcient number (≥ 60) of subjects who had consumed ‘energy
drinks’, were available to estimate statistically robust 95th percentiles.
Table D.2: Daily theobromine intake for all subjects by age class and food group across different
dietary surveys from added ﬂavourings and other sources
Age class Food groups
Mean theobromine intake
95th percentile theobromine
intake(a)
mg per day
mg/kg bw per
day
mg per day
mg/kg bw per
day
Min(b) Max(b) Min(b) Max(b) Min(b) Max(b) Min(b) Max(b)
Toddlers
(12 to
< 36 months;
10 surveys)
Flavouring sources 0.0 1.3 0.0 0.1 0.0 4.6 0.0 0.3
Chocolate 0.9 43 0.1 2.9 3.3 59 0.3 4.9
Tea 0.0 1.6 0.0 0.1 0.0 11 0.0 0.8
‘Energy drinks’ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes(c) 0.9 43 0.1 2.9 3.3 60 0.3 4.9
Other children
(3 to < 10 years;
18 surveys)
Flavouring sources 0.0 1.6 0.0 0.1 0.0 6.7 0.0 0.4
Chocolate 11 57 0.5 2.3 43 177 1.9 7.1
Tea 0.0 7.7 0.0 0.3 0.0 15 0.0 0.7
‘Energy drinks’ 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 11 58 0.5 2.3 43 182 2.0 7.1
Adolescents
(10 to < 18
years; 17
surveys)
Flavouring sources 0.0 1.3 0.0 0.0 0.0 5.7 0.0 0.1
Chocolate 15 77 0.3 1.5 62 294 1.3 6.5
Tea 0.0 7.9 0.0 0.2 0.0 24 0.0 0.4
‘Energy drinks’(d) 0.0 1.8 0.0 0.0 0.0 13 0.0 0.3
Total intakes 19 78 0.3 1.5 65 294 1.4 6.5
Adults
(18 to < 65
years; 18
surveys)
Flavouring sources 0.0 0.9 0.0 0.0 0.0 4.0 0.0 0.1
Chocolate 9.1 41 0.1 0.6 46 165 0.6 2.5
Tea 0.1 11 0.0 0.1 0.0 34 0.0 0.5
‘Energy drinks’(e) 0.0 1.4 0.0 0.0 0.0 11 0.0 0.1
Total intakes 10 47 0.2 0.7 57 174 0.8 2.6
Flavouring Group Evaluation 49 Revision 1
www.efsa.europa.eu/efsajournal 38 EFSA Journal 2017;15(4):4729
Table D.3: Daily caffeine intake from all dietary sources by country survey and age class
Age class Country Survey
Number of
subjects
Caffeine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Toddlers
(12 to < 36
months)
10 surveys
Belgium Regional Flanders 36 20 – 1.5 –
Bulgaria NUTRICHILD 428 3.0 17 0.3 1.4
Denmark IAT 2006-2007 917 3.7 12 0.3 0.9
Finland DIPP 2001-2009 500 0.4 0.9 0.0 0.1
Germany VELS 348 6.2 27 0.5 2.2
Italy INRAN SCAI 2005-2006 36 3.8 – 0.3 –
Netherlands VCP kids 322 10 49 0.7 3.5
Spain enKid 17 18 – 1.2 –
United Kingdom NDNS-Rolling Programme
Years 1-3
185 5.1 31 0.4 2.2
DNSIYC 2011 1,314 2.1 7.8 0.2 0.7
Other children
(3 to
< 10 years)
17 surveys
Austria ASNS_Children 128 19 60 0.6 2.0
Belgium Regional Flanders 625 14 50 0.8 3.0
Bulgaria NUTRICHILD 433 3.9 22 0.2 1.5
Czech Republic SISP04 389 47 94 2.0 4.0
Denmark DANSDA 2005-2008 298 19 47 0.7 1.9
Finland DIPP 2001-2009 750 11 39 0.6 2.0
France INCA2 482 22 66 1.0 3.0
Germany EsKiMo 835 18 59 0.7 2.2
VELS 293 14 47 0.8 2.7
Age class Food groups
Mean theobromine intake
95th percentile theobromine
intake(a)
mg per day
mg/kg bw per
day
mg per day
mg/kg bw per
day
Min(b) Max(b) Min(b) Max(b) Min(b) Max(b) Min(b) Max(b)
Elderly
(65 to < 75
years; 14
surveys)
Flavourings sources 0.0 1.4 0.0 0.0 0.0 6.0 0.0 0.1
Chocolate 3.6 26 0.1 0.4 26 102 0.3 1.4
Tea 0.4 15 0.0 0.2 4.3 37 0.0 0.5
‘Energy drinks’ 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 4.6 33 0.1 0.5 28 102 0.4 1.4
Very elderly
(≥ 75 years; 12
surveys)
Flavourings sources 0.0 1.1 0.0 0.0 0.0 6.0 0.0 0.1
Chocolate 4.4 38 0.1 0.5 28 87 0.4 1.4
Tea 0.2 15 0.0 0.2 6.5 34 0.1 0.5
‘Energy drinks’ 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0
Total intakes 5.8 44 0.1 0.6 36 103 0.6 1.6
bw: body weight.
(a): The 95th percentile estimates obtained from dietary surveys and age classes with less than 60 subjects may not be
statistically robust (EFSA, 2011b) and were consequently not considered in this table.
(b): Ranges of minimum and maximum of mean and 95th percentiles values across the number of individual surveys indicated
for each age class.
(c): ‘Total intakes’ reﬂect the minimum and maximum intakes calculated across the individual surveys for all food categories. N.B.
Total intakes are not derived by summing the values in each column for each age group.
(d): Only one study (the Netherlands) with a sufﬁcient number (≥ 60) of subjects who had consumed ‘energy drinks’ was
available to estimate a statistically robust 95th percentile.
(e): Only two studies (the Netherlands and Ireland) with a sufﬁcient number (≥ 60) of subjects who had consumed ‘energy
drinks’, were available to estimate statistically robust 95th percentiles.
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Age class Country Survey
Number of
subjects
Caffeine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Greece Regional Crete 838 10 35 0.5 1.7
Italy INRAN SCAI 2005-2006 193 27 83 1.1 4.5
Latvia EFSA TEST 187 45 98 1.5 3.9
Netherlands VCP kids 957 17 62 0.8 3.2
VCPBasis AVL2007-2010 447 29 104 1.0 3.9
Spain enKid 156 23 60 0.9 2.7
NUT INK05 399 20 54 0.8 2.0
Sweden NFA 1,473 13 46 0.5 1.8
United Kingdom NDNS-Rolling Programme
Years 1-3
651 11 51 0.5 1.9
Adolescents
(10 to < 18
years)
16 surveys
Austria ASNS_Children 237 24 99 0.5 2.2
Belgium Diet National 2004 576 79 212 1.3 3.5
Cyprus Childhealth 303 38 134 0.7 2.4
Czech Republic SISP04 298 50 120 1.1 2.5
Denmark DANSDA 2005-2008 377 36 99 0.7 1.8
Finland NWSSP07-08 306 55 179 1.0 3.5
France INCA2 973 33 104 0.7 2.0
Germany National Nutrition Survey
II
1,011 63 222 1.0 3.6
EsKiMo 393 24 73 0.6 2.0
Italy INRAN SCAI 2005-2006 247 46 144 0.9 2.5
Latvia EFSA TEST 453 69 158 1.4 3.1
Netherlands VCP Basis AVL2007-2010 1,142 77 226 1.4 4.3
Spain AESAN FIAB 86 43 120 0.7 2.5
enKid 209 25 63 0.5 1.5
NUT INK05 651 40 96 0.7 1.8
Sweden NFA 1,018 22 72 0.5 1.8
United Kingdom NDNS-Rolling Programme
Years 1-3
666 42 138 0.8 2.4
Adults
(18 to < 65
years)
16 surveys
Austria ASNS_Adults 308 128 302 1.8 4.5
Belgium Diet National 2004 1,292 201 553 2.8 7.6
Czech Republic SISP04 1,666 125 270 1.7 3.8
Denmark DANSDA 2005-2008 1,739 323 745 4.3 10
Finland FINDIET2012 1,295 237 540 3.1 6.9
France INCA2 2,276 156 416 2.3 6.4
Germany National Nutrition Survey
II
10,419 236 538 3.1 7.2
Hungary National Repr Surv 1,074 106 268 1.5 3.9
Ireland NANS 2012 1,274 151 346 2.0 4.7
Italy INRAN SCAI 2005-2006 2,313 140 324 2.1 4.8
Latvia EFSA TEST 1,271 150 310 2.0 4.4
Netherlands VCP Basis AVL2007-2010 2,057 265 596 3.4 7.8
Romania Dieta Pilot Adults 1,254 37 110 0.5 1.6
Spain AESAN 410 57 167 0.8 2.6
Spain AESAN FIAB 981 69 162 1.1 2.7
Sweden Riksmaten 2010 1,430 187 405 2.5 5.7
United Kingdom NDNS-Rolling Programme
Years 1-3
1,266 142 323 1.9 4.5
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Age class Country Survey
Number of
subjects
Caffeine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Elderly
(65 to < 75
years)
13 surveys
Austria ASNS_Adults 67 125 242 1.6 3.5
Belgium Diet National 2004 511 217 467 3.0 6.4
Denmark DANSDA 2005-2008 274 363 716 4.9 10
Finland FINDIET2012 413 215 416 2.8 5.9
France INCA2 264 131 309 1.9 4.4
Germany National Nutrition Survey
II
2,006 233 472 3.0 6.1
Hungary National Repr Surv 206 77 179 1.0 2.3
Ireland NANS 2012 149 168 349 2.3 5.1
Italy INRAN SCAI 2005-2006 290 123 322 1.7 4.6
Netherlands VCPBasis AVL2007-2010 173 282 548 3.7 7.6
Netherlands VCP-Elderly 289 267 470 3.5 6.1
Romania Dieta Pilot Adults 83 23 96 0.3 1.5
Sweden Riksmaten 2010 295 206 389 2.8 5.1
United Kingdom NDNS-Rolling Programme
Years 1-3
166 166 378 2.2 5.3
Very elderly
(≥ 75 years)
11 surveys
Austria ASNS_Adults 25 146 – 2.0 –
Belgium Diet National 2004 704 197 423 2.8 6.3
Denmark DANSDA 2005-08 12 417 – 6.0 –
France INCA2 84 108 272 1.6 3.8
Germany National Nutrition Survey
II
490 197 373 2.7 5.2
Hungary National Repr Surv 80 70 174 1.0 2.3
Ireland NANS 2012 77 160 292 2.4 5.9
Italy INRAN SCAI 2005-2006 228 102 263 1.5 4.2
Netherlands VCP-Elderly 450 240 456 3.2 5.9
Romania Dieta Pilot Adults 45 22 – 0.3 –
Sweden Riksmaten 2010 72 172 268 2.4 4.0
United Kingdom NDNS-Rolling Programme
Years 1-3
139 152 305 2.2 4.7
bw: body weight.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 subjects may not be statistically
robust (EFSA, 2011b) and were consequently not considered (‘–’).
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Table D.4: Daily theobromine intake from all dietary sources by country survey and age class
Age class Country Survey
Number of
subjects
Theobromine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Toddlers
(12 to < 36
months)
10 surveys
Belgium Regional Flanders 36 26 – 1.9 –
Bulgaria NUTRICHILD 428 5.3 28 0.4 2.5
Denmark IAT 2006-2007 917 16 52 1.2 4.0
Finland DIPP 2001-2009 500 0.9 3.3 0.1 0.3
Germany VELS 348 18 59 1.4 4.9
Italy INRAN SCAI 2005-2006 36 5.7 – 0.5 –
Netherlands VCP kids 322 17 60 1.2 4.2
Spain enKid 17 43 – 2.9 –
United Kingdom NDNS-Rolling
Programme Years 1-3
185 5.4 20 0.4 1.6
DNSIYC 2011 1,314 4.6 17 0.4 1.6
Other children
(3 to < 10
years) 17 surveys
Austria ASNS_Children 128 34 102 1.1 3.5
Belgium Regional Flanders 625 20 57 1.1 3.4
Bulgaria NUTRICHILD 433 11 60 0.7 3.6
Czech Republic SISP04 389 46 122 1.9 5.5
Denmark DANSDA 2005-2008 298 47 116 1.8 4.5
Finland DIPP 2001-2009 750 23 81 1.2 4.2
France INCA2 482 41 121 1.9 5.6
Germany EsKiMo 835 44 119 1.6 4.4
VELS 293 37 110 2.2 6.2
Greece Regional Crete 838 20 68 0.9 3.4
Italy INRAN SCAI 2005-2006 193 28 112 1.2 5.0
Latvia EFSA TEST 187 58 182 2.0 7.0
Netherlands VCP kids 957 24 68 1.3 3.5
VCPBasis AVL2007-2010 447 35 95 1.2 3.5
Spain enKid 156 57 165 2.3 7.1
NUT INK05 399 48 117 1.8 4.5
Sweden NFA 1,473 13 55 0.5 2.1
United Kingdom NDNS-Rolling
Programme Years 1-3
651 12 43 0.5 2.0
Adolescents
(10 to < 18
years) 16 surveys
Austria ASNS_Children 237 20 68 0.5 1.7
Belgium Diet National 2004 576 53 174 0.9 2.8
Cyprus Childhealth 303 41 127 0.9 2.8
Czech Republic SISP04 298 39 119 0.9 3.3
Denmark DANSDA 2005-2008 377 58 180 1.2 3.5
Finland NWSSP07-08 306 78 294 1.5 6.5
France INCA2 973 40 126 0.8 2.7
Germany National Nutrition
Survey II
1,011 35 143 0.6 2.5
EsKiMo 393 45 117 1.2 3.2
Italy INRAN SCAI 2005-2006 247 29 119 0.6 2.3
Latvia EFSA TEST 453 64 264 1.3 5.1
Netherlands VCP Basis AVL2007-
2010
1,142 45 133 0.9 2.8
Spain AESAN FIAB 86 48 146 0.8 2.6
enKid 209 54 164 1.1 3.1
NUT INK05 651 53 139 1.1 3.2
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Age class Country Survey
Number of
subjects
Theobromine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Sweden NFA 1,018 19 82 0.5 2.1
United Kingdom NDNS-Rolling
Programme Years 1-3
666 18 65 0.3 1.4
Adults (18 to
< 65 years) 16
surveys
Austria ASNS_Adults 308 20 75 0.3 1.1
Belgium Diet National 2004 1,292 33 129 0.5 2.0
Czech Republic SISP04 1,666 18 74 0.3 1.0
Denmark DANSDA 2005-2008 1,739 47 141 0.7 2.0
Finland FINDIET2012 1,295 22 107 0.3 1.5
France INCA2 2,276 23 88 0.3 1.3
Germany National Nutrition
Survey II
10,419 24 110 0.3 1.5
Hungary National Repr Surv 1,074 30 122 0.4 1.7
Ireland NANS 2012 1,274 24 71 0.3 1.0
Italy INRAN SCAI 2005-2006 2,313 10 57 0.2 0.8
Latvia EFSA TEST 1,271 36 174 0.5 2.6
Netherlands VCP Basis AVL2007-
2010
2,057 33 108 0.4 1.5
Romania Dieta Pilot Adults 1,254 14 82 0.2 1.1
Spain AESAN 410 30 121 0.4 1.7
Spain AESAN FIAB 981 28 137 0.4 2.1
Sweden Riksmaten 2010 1,430 17 69 0.2 1.0
United Kingdom NDNS-Rolling
Programme Years 1-3
1,266 21 64 0.3 0.9
Elderly (65 to
< 75 years) 13
surveys
Austria ASNS_Adults 67 16 70 0.2 0.9
Belgium Diet National 2004 511 23 102 0.3 1.4
Denmark DANSDA 2005-2008 274 33 100 0.5 1.3
Finland FINDIET2012 413 9.8 55 0.1 0.8
France INCA2 264 14 61 0.2 1.0
Germany National Nutrition
Survey II
2,006 16 79 0.2 1.1
Hungary National Repr Surv 206 15 73 0.2 0.9
Ireland NANS 2012 149 24 73 0.3 1.0
Italy INRAN SCAI 2005-2006 290 4.6 28 0.1 0.4
Netherlands VCPBasis AVL2007-2010 173 21 73 0.3 1.0
Netherlands VCP-Elderly 289 26 79 0.3 1.2
Romania Dieta Pilot Adults 83 6.8 49 0.1 0.7
Sweden Riksmaten 2010 295 12 57 0.2 0.9
United Kingdom NDNS-Rolling
Programme Years 1-3
166 24 72 0.3 1.0
Very elderly
(≥ 75 years) 11
surveys
Austria ASNS_Adults 25 23 – 0.3 –
Belgium Diet National 2004 704 17 86 0.2 1.2
Denmark DANSDA 2005-08 12 44 – 0.6 –
France INCA2 84 23 65 0.4 1.1
Germany National Nutrition
Survey II
490 17 75 0.2 1.1
Hungary National Repr Surv 80 19 66 0.3 1.1
Ireland NANS 2012 77 22 55 0.3 0.8
Italy INRAN SCAI 2005-2006 228 5.8 36 0.1 0.6
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Age class Country Survey
Number of
subjects
Theobromine intake
mg per day
mg/kg bw per
day
Mean P95(a) Mean P95(a)
Netherlands VCP-Elderly 450 29 85 0.4 1.1
Romania Dieta Pilot Adults 45 11 – 0.1 –
Sweden Riksmaten 2010 72 13 67 0.2 0.8
United Kingdom NDNS-Rolling
Programme Years 1-3
139 28 103 0.4 1.6
bw: body weight.
(a): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 subjects may not be statistically
robust (EFSA, 2011b) and were consequently not considered (‘–’).
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Appendix E – Food sources contributing to daily caffeine and theobromine
intake
Table E.1: Food sources contributing to daily caffeine intake
Population
group
Country Survey
Food sources contributing to daily caffeine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
Toddlers
(12 to < 36
months)
Belgium Regional Flanders 68 22 9.6 0.0 0.0
Bulgaria NUTRICHILD 3.1 49 0.0 0.0 48
Denmark IAT 2006 07 9.8 60 0.8 0.0 29
Finland DIPP 2001 2009 16 78 5.5 0.0 0.0
Germany VELS 7.4 80 0.3 0.0 12
Italy INRAN SCAI 2005 06 13 36 0.0 0.0 51
Netherlands VCP kids 13 19 2.4 0.0 66
Spain enKid 0.0 100 0.0 0.0 0.0
United Kingdom DNSIYC 2011 2.8 62 0.2 0.3 35
NDNS-Rolling Programme
Years 1-3
11 17 0.1 0.0 73
Median 10 55 0.3 0.0 32
Range (0–68) (17–100) (0–10) (0) (0–73)
Austria ASNS_Children 6.0 44 3.0 1.1 46
Other
children
(3 to < 10
years)
Belgium Regional Flanders 65 15 14 0.1 5.5
Bulgaria NUTRICHILD 25 69 0.0 0.0 6.1
Czech Rep. SISP04 0.6 27 5.3 0.0 67
Denmark DANSDA 2005-08 51 34 2.2 0.0 12
Finland DIPP 2001 2009 22 71 5.9 0.0 1.2
France INCA2 24 63 6.3 0.0 7.5
Germany EsKiMo 16 52 1.9 0.5 30
VELS 7.1 81 0.2 0.0 12
Greece Regional Crete 17 78 1.7 0.0 3.4
Italy INRAN SCAI 2005 06 12 32 38 0.0 18
Latvia EFSA TEST 3.3 19 14 0.0 64
Netherlands VCPBasis AVL2007 2010 28 19 2.2 1.1 50
VCP kids 25 16 2.1 0.0 57
Spain NUT INK05 16 82 2.6 0.0 0.3
enKid 0.6 96 3.3 0.0 0.0
Sweden NFA 58 30 1.8 0.5 9.5
United Kingdom NDNS-Rolling Programme
Years 1-3
36 19 2.0 2.4 41
Median 19 39 2.4 0.0 12
Range (1–65) (15–96) (0–38) (0–2) (0–67)
Austria ASNS_Children 7.3 16 18 7.1 52
Adolescents
(10 to < 18
years)
Belgium Diet National 2004 47 13 21 4.6 15
Cyprus Childhealth 0.4 38 53 0.0 9.2
Czech Rep. SISP04 0.5 20 14 0.0 65
Denmark DANSDA 2005-08 43 21 15 0.0 21
Finland NWSSP07 08 19 58 19 3.4 2.0
France INCA2 29 35 21 0.0 15
Germany EsKiMo 27 39 2.4 0.8 31
National Nutrition Survey II 23 15 31 0.0 31
Italy INRAN SCAI 2005 06 20 19 40 0.6 21
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Population
group
Country Survey
Food sources contributing to daily caffeine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
Latvia EFSA TEST 3.6 11 32 0.3 53
Netherlands VCPBasis AVL2007 2010 30 11 13 7.4 39
Spain AESAN FIAB 21 39 38 0.0 1.0
NUT INK05 29 49 21 0.0 1.9
enKid 0.6 87 13 0.0 0.0
Sweden NFA 53 27 2.2 1.3 17
United Kingdom NDNS-Rolling Programme
Years 1-3
41 6.6 9.0 9.2 35
Median 23 20.8 19 0.3 21
Range (0–53) (7–87) (2–53) (0–9) (0–65)
Adults
(18 to ≤ 65
years)
Austria ASNS_Adults 1.9 1.6 80 0.8 16
Belgium Diet National 2004 13 2.7 79 0.7 5.5
Czech Rep. SISP04 0.1 2.6 72 0.0 26
Denmark DANSDA 2005-08 2.9 2.0 87 0.0 8.1
Finland FINDIET2012 1.5 2.0 93 0.6 2.5
France INCA2 4.1 3.0 80 0.0 13
Germany National Nutrition Survey II 4.4 1.9 83 0.0 11
Hungary National Repr Surv 7.2 8.3 56 0.0 29
Ireland NANS 2012 5.4 1.3 32 2.9 59
Italy INRAN SCAI 2005 06 2.2 1.9 91 0.1 5.0
Latvia EFSA TEST 0.9 2.2 75 0.1 22
Netherlands VCPBasis AVL2007 2010 8.5 1.7 68 1.3 20
Romania Dieta Pilot Adults 4.3 12 82 0.3 2.1
Spain AESAN 23 15 39 3.8 19
AESAN FIAB 12 14 74 0.3 0.7
Sweden Riksmaten 2010 4.0 1.0 82 0.3 12
United Kingdom NDNS-Rolling Programme
Years 1-3
9.2 1.4 33 1.1 55
Median 4.3 2.0 79 0.3 13
Range (0–23) (1–15) (32–93) (0–4) (1–59)
Austria ASNS_Adults 0.1 1.3 77 0.5 21
Elderly
(65 to < 75
years)
Belgium Diet National 2004 1.6 1.6 92 0.2 4.1
Denmark DANSDA 2005-08 0.6 1.4 91 0.0 7.0
Finland FINDIET2012 0.2 1.0 97 0.0 1.7
France INCA2 0.7 1.5 79 0.0 19
Germany National Nutrition Survey II 0.7 0.9 86 0.0 13
Hungary National Repr Surv 2.8 5.2 57 0.0 35
Ireland NANS 2012 1.2 1.6 23 0.0 74
Italy INRAN SCAI 2005 06 0.4 0.8 92 0.0 6.6
Netherlands VCP-Elderly 1.1 1.1 73 0.0 25
VCPBasis AVL2007 2010 1.8 0.6 79 0.0 19
Romania Dieta Pilot Adults 0.1 10 84 0.0 6.3
Sweden Riksmaten 2010 0.6 0.7 88 0.0 11
United Kingdom NDNS-Rolling Programme
Years 1-3
1.2 1.2 33 0.4 65
Median 0.7 1.3 81 0.0 16
Range (0–3) (1–10) (23–97) (0–1) (2–74)
Austria ASNS_Adults 0.7 1.0 72 0.0 26
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Table E.2: Food sources contributing to daily theobromine intake
Population
group
Country Survey
Food sources contributing to daily theobromine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
Toddlers
(12 to < 36
months)
Belgium Regional Flanders 5.1 95 0.0 0.0 0.0
Bulgaria NUTRICHILD 0.0 93 0.0 0.0 6.7
Denmark IAT 2006 07 1.3 97 0.0 0.0 1.7
Finland DIPP 2001 2009 0.0 100 0.0 0.0 0.0
Germany VELS 1.2 96 0.0 0.0 2.8
Italy INRAN SCAI 2005 06 0.0 93 0.0 0.0 7.1
Netherlands VCP kids 3.6 87 0.0 0.0 9.6
Spain enKid 0.0 100 0.0 0.0 0.0
United Kingdom DNSIYC 2011 0.1 96 0.0 0.0 3.8
NDNS-Rolling Programme
Years 1-3
0.6 91 0.0 0.0 8.7
Median 0.3 95 0.0 0.0 3.3
Range (0–5) (87–100) (0) (0) (0–10)
Austria ASNS_Children 3.8 90 0.0 0.2 6.1
Other children
(3 to < 10
years)
Belgium Regional Flanders 8.0 91 0.0 0.0 1.0
Bulgaria NUTRICHILD 0.2 99 0.0 0.0 0.6
Czech Rep. SISP04 0.3 83 0.0 0.0 17
Denmark DANSDA 2005-08 1.6 97 0.0 0.0 1.2
Finland DIPP 2001 2009 0.0 100 0.0 0.0 0.2
France INCA2 0.2 99 0.0 0.0 1.0
Germany EsKiMo 1.0 96 0.0 0.1 3.0
VELS 1.4 97 0.0 0.0 1.6
Greece Regional Crete 1.3 98 0.0 0.0 0.4
Italy INRAN SCAI 2005 06 0.0 97 0.0 0.0 3.3
Population
group
Country Survey
Food sources contributing to daily caffeine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
Very elderly
(≥ 75 years)
Belgium Diet National 2004 1.4 1.1 93 0.0 4.9
Denmark DANSDA 2005-08 0.2 2.2 92 0.0 5.9
France INCA2 0.6 7.1 81 0.0 11
Germany National Nutrition Survey II 0.2 1.3 84 0.0 15
Hungary National Repr Surv 1.7 7.2 41 0.0 50
Ireland NANS 2012 0.1 1.2 20 0.0 78
Italy INRAN SCAI 2005 06 0.4 1.5 88 1.0 9.0
Netherlands VCP-Elderly 0.8 1.5 66 0.1 32
Romania Dieta Pilot Adults 1.8 18 77 0.0 3.9
Sweden Riksmaten 2010 0.1 0.9 88 0.0 12
United Kingdom NDNS-RollingProgramme
Years 1-3
0.8 3.3 28 0.2 68
Median 0.6 1.5 79 0.0 13
Range (0–2) (1–18) (20–93) (0–1) (4–78)
(a): For dietary surveys included in the 2010 release, which was based on the FoodEx classiﬁcation, products coded as ‘carbohydrate-rich energy food
products for sports people’ or ‘carbohydrate-electrolyte solutions for sports people’ at the 3rd level of FoodEx, within the ﬁrst level category of
‘Products for special nutritional use’, were used to calculate caffeine consumption from ‘energy drinks’ and their contribution to total caffeine intake.
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Population
group
Country Survey
Food sources contributing to daily theobromine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
Latvia EFSA TEST 0.0 89 0.0 0.0 11
Netherlands VCPBasis AVL2007 2010 2.4 90 0.0 0.3 7.8
VCP kids 3.6 87 0.0 0.0 9.6
Spain NUT INK05 0.3 100 0.0 0.0 0.0
enKid 0.0 100 0.0 0.0 0.0
Sweden NFA 6.4 91 0.0 0.2 2.4
United Kingdom NDNS-Rolling Programme
Years 1-3
1.2 93 0.0 0.7 4.7
Median 1 96 0 0 2
Range (0–8) (83–100) (0) (0–1) (0–17)
Austria ASNS_Children 6.4 77 0.0 2.6 15
Adolescents
(10 to < 18
years)
Belgium Diet National 2004 0.4 92 0.0 2.1 5.0
Cyprus Childhealth 0.1 98 0.0 0.0 2.1
Czech Rep. SISP04 0.2 79 0.0 0.0 21
Denmark DANSDA 2005-08 1.9 95 0.0 0.0 3.3
Finland NWSSP07 08 0.0 99 0.0 0.7 0.4
France INCA2 0.3 97 0.0 0.0 2.9
Germany EsKiMo 1.3 94 0.0 0.1 4.1
National Nutrition Survey
II
0.3 88 0.0 0.0 12
Italy INRAN SCAI 2005 06 0.0 94 0.0 0.3 6.1
Latvia EFSA TEST 0.1 88 0.0 0.1 12
Netherlands VCPBasis AVL2007 2010 1.7 82 0.0 3.9 12
Spain AESAN FIAB 0.0 100 0.0 0.0 0.2
NUT INK05 0.4 99 0.0 0.0 0.3
enKid 0.1 100 0.0 0.0 0.0
Sweden NFA 5.0 90 0.0 0.5 4.5
United Kingdom NDNS-Rolling Programme
Years 1-3
2.2 81 0.0 6.7 9.8
Median 0 94 0 0 5
Range (0–6) (77–100) (0) (0–7) (0–21)
Austria ASNS_Adults 3.7 71 0.0 1.7 23
Adults
(18 to ≤ 65
years)
Belgium Diet National 2004 2.0 90 0.0 1.3 7
Czech Rep. SISP04 0.1 57 0.0 0.0 43
Denmark DANSDA 2005-08 1.0 86 0.0 0.0 13
Finland FINDIET2012 0.0 90 0.0 1.9 7.9
France INCA2 0.4 77 0.0 0.0 22
Germany National Nutrition Survey
II
0.4 81 0.0 0.0 19
Hungary National Repr Surv 2.9 84 0.0 0.0 13
Ireland NANS 2012 0.9 47 0.0 5.9 46
Italy INRAN SCAI 2005 06 0.0 89 0.0 0.6 10
Latvia EFSA TEST 0.0 80 0.0 0.2 20
Netherlands VCPBasis AVL2007 2010 2.7 68 0.0 3.2 26
Romania Dieta Pilot Adults 0.1 98 0.0 0.2 1.3
Spain AESAN 0.4 89 0.0 2.2 8.6
AESAN FIAB 0.3 99 0.0 0.2 0
Sweden Riksmaten 2010 0.8 77 0.0 1.1 21
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Population
group
Country Survey
Food sources contributing to daily theobromine intake (%)
Flavoured foods
and beverages
Chocolate Coffee
Energy
Drinks(a)
Tea
United Kingdom NDNS-Rolling Programme
Years 1-3
3.1 48 0.0 2.4 47
Median 0 80 0 1 19
Range (0–4) (47–99) (0) (0–6) (0–47)
Austria ASNS_Adults 8.9 57 0.0 1.2 33
Elderly (65 to
< 75 years)
Belgium Diet National 2004 1.4 91 0.0 0.7 7.1
Denmark DANSDA 2005-08 1.0 80 0.0 0.0 19
Finland FINDIET2012 1.0 88 0.0 0.2 11
France INCA2 0.3 58 0.0 0.0 42
Germany National Nutrition Survey
II
0.4 69 0.0 0.0 31
Hungary National Repr Surv 7.7 72 0.0 0.0 21
Ireland NANS 2012 0.8 38 0.0 0.0 62
Italy INRAN SCAI 2005 06 0.0 78 0.0 0.0 22
Netherlands VCP-Elderly 2.0 61 0.0 0.0 37
VCPBasis AVL2007 2010 4.7 59 0.0 0.0 37
Romania Dieta Pilot Adults 0.0 95 0.0 0.0 5.4
Sweden Riksmaten 2010 0.2 73 0.0 0.0 27
United Kingdom NDNS-Rolling Programme
Years 1-3
2.8 37 0.0 0.9 59
Median 1 70 0 0 29
Range (0–9) (37–95) (0) (0–1) (5–62)
Austria ASNS_Adults 0.7 67 0.0 0.0 32
Very elderly
(≥ 75 years)
Belgium Diet National 2004 2.2 89 0.0 0.1 8.7
Denmark DANSDA 2005-08 0.2 86 0.0 0.0 13
France INCA2 0.1 87 0.0 0.0 13
Germany National Nutrition Survey
II
2.4 70 0.0 0.0 27
Hungary National Repr Surv 5.8 72 0.0 0.0 23
Ireland NANS 2012 0.7 31 0.0 0.0 68
Italy INRAN SCAI 2005 06 0.0 75 0.0 5.3 20
Netherlands VCP-Elderly 2.4 62 0.0 0.3 36
Romania Dieta Pilot Adults 0.0 98 0.0 0.0 2.1
Sweden Riksmaten 2010 0.2 77 0.0 0.0 23
United Kingdom NDNS-RollingProgramme
Years 1-3
2.6 51 0.0 0.3 46
Median 1 73 0 0 23
Range (0–6) (31–98) (0) (0–5) (2–68)
(a): For dietary surveys included in the 2010 release, which was based on the FoodEx classiﬁcation, products coded as ‘carbohydrate-rich energy food
products for sports people’ or ‘carbohydrate-electrolyte solutions for sports people’ at the 3rd level of FoodEx, within the ﬁrst level category of
‘Products for special nutritional use’, were used to calculate caffeine consumption from ‘energy drinks’ and their contribution to total caffeine
intake.
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Appendix F – Absorption, distribution, metabolism and elimination
The pharmacokinetics and metabolism of caffeine and theobromine have been extensively reviewed
by Arnaud (Arnaud, 2011).
Caffeine [FL-no: 16.016]
Absorption, distribution and elimination
Caffeine is rapidly and completely absorbed from the intestinal tract after oral intake, without
appreciable ﬁrst pass metabolism (Yesair et al., 1984; Arnaud, 2011). The pharmacokinetics of the
substance in humans have been reviewed by Arnaud (Arnaud, 2011) and the following data were
taken from that review and a few additional papers.
Peak plasma levels of 3 mg/L (range 2.0–4.0) occurred within 1 h after ingestion of 120 mg
caffeine by 13 subjects (Routh et al., 1969); similar results were found by other authors (see Arnaud,
2011). As compared to capsule formulation of caffeine, the plasma peak concentration of caffeine in
chocolate or cola showed a somewhat delayed absorption: the plasma peak occurred after 1.5–2 h
instead of 30 min.
Caffeine is distributed across total body water and occurs in all body ﬂuids. The unbound volume of
distribution is 1.06 L/kg. Autoradiography of radiolabelled caffeine showed that there was no long-term
accumulation in any tissue in the rat (Arnaud, 1976). Caffeine was shown to cross the blood–brain
barrier in the rat and horse which, given the CNS effects of caffeine in humans, was to be expected.
The substance also crosses the placenta to reach the foetus.
Caffeine is efﬁciently eliminated via the urine. The mean plasma terminal half-life is 4 h in adults
(range 3–10 h) (Parsons and Neims, 1978; Lelo et al., 1986a). The mean systemic clearance in
humans is of the order of 80 mL/min, mainly by metabolism in the liver. Most of the ingested amount
is excreted as metabolites in the urine whereas less than 5% of the oral dose is eliminated unchanged
(Callahan et al., 1982; Arnaud, 2011). The half-life of excretion of the metabolites may be more than
twice the elimination half-life of caffeine from plasma (Callahan et al., 1982). At higher caffeine intake
(70 mg or more), saturation of certain metabolic pathways may occur, leading to reduced clearance
(Arnaud, 2011).
Metabolism
The metabolism of caffeine is rather complex and genetic polymorphisms within the human
population lead to considerable variation in the metabolite pattern of the substance (Grant et al.,
1983; Miners and Birkett, 1996; Arnaud, 2011). It has been extensively studied because of its use as a
probe for several biotransformation pathways in humans: a massive body of information (see below)
has been accumulated since the seventies of the last century.
Caffeine gives rise to at least 17 metabolites in urine (see Table F.1); (CYP-mediated)
demethylation, hydroxylation and acetylation play a major role. It has been used as an in vivo probe
for hepatic CYP1A2 for screening purposes: CYP1A2 catalyses the demethylation reactions and is
responsible for some 90% of the caffeine clearance. In contrast, the C8-hydroxylation (in vitro) is
almost entirely catalysed by CYP3A4. Also, xanthine oxidase plays a role in the oxidative reactions. The
large interindividual variability of CYP1A2 activity in the human population inﬂuences the disposition of
caffeine (Landi et al., 1999); these variations may be due to factors such as gender, race, genetic
polymorphisms, and exposure to inducers (Rasmussen et al., 2002). The molar ratios of metabolites of
caffeine used as an index of CYP1A2 activity in populations are distributed according to bimodal or
trimodal distributions, and normal or unimodal distributions have also been suggested (Landi et al.,
1999). At least two distinct liver CYP enzymes with different substrate afﬁnities have the potential to
catalyse caffeine N-demethylations and C8-hydroxylations in vitro but at the low concentrations
routinely encountered in vivo, participation by the high-afﬁnity site is expected to predominate.
Major human metabolites are 1-methylxanthine, 7-methylxanthine (7-MX), 1,7-dimethylxanthine
(paraxanthine), 1,7-dimethyluric acid, 1-methyluric acid and 5-acetylamino-6-formylamino-3-
methyluracil (AFMU) (see Table F.1). Part of caffeine is metabolised through theobromine (3,7-
dimethylxanthine) and theophylline (1,3-dimethylxanthine), which are further metabolised to the major
caffeine metabolites.
The mean fractional conversion of caffeine to paraxanthine, theobromine and theophylline was
80  21%, 10.8  2.4% and 3.7  1.3%, respectively (Lelo et al., 1986b). This was based on
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extensive pharmacokinetic studies in six human volunteers. They were dosed sequentially with
equimolar doses of caffeine (270 mg), as well as its mono-demethylated metabolites theobromine,
theophylline and paraxanthine (250 mg). For each of these compounds and each volunteer, the
pharmacokinetics based on their plasma levels were determined (Lelo et al., 1986a). Subsequently,
during steady state oral administration of caffeine the partial clearances of each metabolic route in
each volunteer were determined based again on plasma pharmacokinetic data. The fractional
conversion data are therefore based on the initial demethylation step of caffeine metabolism, and are
not inﬂuenced by the fact that some further metabolites may be derived from the same precursor (e.g.
7-MX may be derived from both theobromine and paraxanthine). Moreover, eventual deﬁcits in urinary
excretion of the metabolites do not play a role. Another study found that paraxanthine accounted for
63  13% of the dimethylxanthines in plasma, theobromine 27  15% and theophylline 10  2.6%
(Rodopoulos and Norman, 1996). In this single dose study, plasma concentration and excretion proﬁles
of the major caffeine metabolites were determined and more assumptions were made which,
according to the authors, resulted in an overestimation of the formation of theobromine. However,
these results can be judged to be supportive of the results of Lelo et al. (1986b) above.
The formation of the acetylated metabolite 5-acetylamino-6-formylamino-3-methyluracil (AFMU) is
subject to polymorphism of the N-acetyltransferase NAT2 phenotype. CYP 1A2 and 3A4 are also
responsible for metabolic polymorphisms within populations (Miners and Birkett, 1996; Arnaud, 2011).
This gives rise to a wide range of plasma elimination half-lives (3–10 h) for the metabolites of caffeine.
Other factors that affect metabolism are age, gender and hormones, physical exercise, obesity, drugs,
disease, smoking, diet and alcohol, as reviewed by Arnaud (2011).
None of the caffeine metabolites is chemically reactive and they are readily excreted in urine.
Theobromine [FL-no: 16.032]
Absorption, distribution and elimination
The pharmacokinetics of absorption, metabolism and excretion of theobromine have been reviewed
by Arnaud (2011), from which most of the data below are taken. Most of the theobromine dose
administered orally to rats or humans is absorbed as indicated by the almost complete recovery in the
form of metabolites in urine. Due to matrix interactions, the absorption of theobromine from chocolate
is somewhat slower and less complete (80%). Autoradiography of radiolabelled theobromine in rats
indicated that there was no accumulation in any organ. In man, theobromine is distributed throughout
the total body water (Yesair et al., 1984). It has a volume of distribution comparable to total body
water of approx. 0.8 L/kg bw. It crosses the blood–brain barrier, as well as the placenta; the available
Table F.1: Urinary excretion of caffeine, theophylline and theobromine metabolites in humans (%
of total urinary metabolites) (modiﬁed from Arnaud, 2011)
% Urinary metabolites
Substance orally consumed
Caffeine Theophylline Theobromine
Caffeine 1
Theophylline 1 16
Theobromine 2 20
Paraxanthine (1,7-dimethylxanthine) 6
5-Acetylamino-6-formylamino-3-methyluracil (AFMU) 16
1,7-Dimethyluric acid 6
1,3-Dimethyluric acid 3 47
3,7-Dimethyluric acid 1 1
1-Methylxanthine 19 1
6-Amino-5-[N-formylmethylamino]-1-methyluracil 2 12
7-Methylxanthine 7 36
3-Methylxanthine 3 14 21
7-Methyluric acid 8
1-Methyluric acid 26 20
Other (n = 4) 5
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data in rat suggest that the brain passage of theobromine is less complete than that of caffeine. Peak
plasma concentration is reached after 2–3 h. Its plasma half-life ranges from 7 to 12 h (Arnaud,
2011), somewhat longer than that of caffeine or theophylline. Elimination from plasma was around
0.7–0.9 mL/min per kg bw in human volunteers (Miners et al., 1982; Arnaud, 2011). Some 90% of the
dose of theobromine is excreted in urine as metabolites within 48 h.
Metabolism
Theobromine (3,7-dimethylxanthine) gives rise to a number of metabolites in humans, most of
which are also found after ingestion of caffeine (see Table F.1) (Arnaud, 2011). Thus, Miners et al.
recovered 91% of the 200 mg dose (4 volunteers) in urine, and identiﬁed 3-methylxanthine, 7-
methylxanthine, 7-methyluric acid and 6-Amino-5-[N-formylmethylamino]-1-methyluracil as major
metabolites (Miners et al., 1982). CYP1A2 plays a major role in theobromine metabolism. 3-N-
Demethylation predominates (50–60% of metabolism), while 7-N-demethylation (20%) and C-8
oxidation (less than 15%) contribute as well. Polymorphism of CYP1A2 leads to variation in the
elimination rate of theobromine metabolites. Much less is known about factors inﬂuencing metabolism
of theobromine than is the case for caffeine (Arnaud, 2011).
None of the metabolites of theobromine is chemically reactive.
Theophylline
Theophylline is one of the metabolites of caffeine. It is registered as drug used in asthma and chronic
obstructive pulmonary disease (COPD) at a dose level of 10–20 mg/kg bw (700,000–1,400,000 lg in
a 70-kg person). Side effects at that dose level are gastrointestinal (e.g. nausea and vomiting),
CNS (restlessness), cardiac (tachycardia, arrhythmia).
The major metabolites of the supporting substance theophylline are the same as major caffeine
and theobromine metabolites: 3-methylxanthine, 1-methyluric acid and 1,3-dimethyluric acid; in
addition, in neonates, 7-N-methylation to form caffeine occurs. Dose dependence of pharmacokinetics
in male volunteers has been described (Dadashzadeh and Tajerzaden, 2001). The pharmacokinetics of
theophylline have been reviewed by Arnaud (Arnaud, 2011).
Summary and conclusions
The methylxanthines caffeine and theobromine are rapidly absorbed after oral intake, show little ﬁrst
pass metabolism in gut or liver (Yesair et al., 1984) and are almost completely excreted as such or as
metabolites in urine. Their elimination half-life from plasma is of the order of 4–12 h. Both substances
are distributed over total body water, cross placenta and blood–brain barrier. A very complex mixture of
metabolites is generated in the liver by N-demethylation, 8-hydroxylation and N-acetylation.
Theobromine and theophylline are intermediary metabolites of caffeine, which are further
metabolised. Cytochrome P450 1A2 plays a major role in the N-demethylation reactions, while 3A4
catalyses 8-hydroxylation. N-acetyltransferases catalyse the formation of acetylated metabolites.
Xanthine oxidase also contributes to the formation of the oxidative metabolites of caffeine. Several of
these enzymes show polymorphism in the human population, leading to variation in the elimination
rate of the caffeine and theobromine and their metabolites. Interaction of methylxanthine metabolites
with the food matrix as well as with drugs and other exogenous factors also results in variation in the
rates of elimination of these substances.
Overall, it is anticipated that caffeine, theobromine and their identiﬁed metabolites are innocuous.
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Appendix H – Other evaluations/regulation status
SCF Opinion of the Scientiﬁc Committee on Food on additional information
on ‘energy’ drinks (SCF, 2003)
The Committee was asked to review additional information submitted on energy drinks and indicate
if the conclusions in its opinion of 21 January 1999 needed to be modiﬁed.
Conclusion
‘Based on the submission of further data and developments in EU, the Committee’s earlier Opinion
on caffeine remains unchanged.’
In the SCF Opinion from 1999, it was concluded:
‘For caffeine, it was concluded that the contribution of ‘energy’ drinks to overall caffeine intake was
not a matter of concern for non-pregnant adults. For children who do not normally consume much tea
or coffee, and who might substitute ‘energy’ drinks for cola or other soft drinks, consumption of
‘energy’ drinks might represent an increase in daily caffeine exposure compared with their previous
intake. The Committee considered that this could result in transient behavioural changes, such as
increased arousal, irritability, nervousness or anxiety. For pregnant adults, the Committee concluded
that while intakes of caffeine up to 300 mg per day appeared to be safe, the question of possible
effects on pregnancy and the offspring at regular intakes above 300 mg per day remained open. This
suggested that moderation of caffeine intake, from whatever source, was advisable during pregnancy’
(SCF, 2003).
EU Regulation No 1169/2011 of the European Parliament and of the
Council on the provision of food information to consumers
Regulation (EU) No 1169/2011 requires that beverages containing more than 150 mg/L (other than
those based on coffee or tea) are labelled as ‘High caffeine content’. The following text has to be
included: ‘Not recommended for children or pregnant or breast feeding women’. Also, caffeine content
expressed in mg per 100 mL must be declared.
A new requirement is that foods other than beverages where caffeine is added with a physiological
purpose must be labelled as follows: ‘Contains caffeine. Not recommended for children or pregnant
women.’ Caffeine content in mg per 100 g or mL must also be declared. In the case of food
supplements, the caffeine content shall be expressed per portion as recommended for daily
consumption on the labelling.
EFSA Scientiﬁc Opinion of the Panel on Contaminants in the Food Chain on
‘Theobromine as undesirable substances in animal feed’ (EFSA, 2008)
Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable
substances in animal feed established maximum levels for theobromine in complete feeding stuffs. The
Scientiﬁc Committee on Animal Nutrition concluded that theobromine is a natural constituent of plants
used for feed purposes. Above certain concentrations, they affect the health of domestic animals while
they are without effects on the human consumer of products derived thereof. Any risk posed by feed
ingredients containing these compounds is according to the Scientiﬁc Committee on Animal Nutrition
managed by modern techniques of feed formulation. The Scientiﬁc Committee on Animal Nutrition
therefore recommended that theobromine should be excluded from the list of undesirable substances
in annex to Directive 2002/32/EC as it concerns a natural constituent of feed ingredients which is not
relevant to the control of contamination.
Conclusion
The Panel on Contaminants in the Food Chain (CONTAM Panel) concluded that theobromine
exposure from animal products such as meat, milk and eggs is expected to be negligible in comparison
with direct consumption of cocoa products (EFSA, 2008).
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EFSA Scientiﬁc Opinion of the Panel on Dietetic Products, Nutrition and
Allergies (NDA) on ‘the safety of caffeine’ (EFSA NDA Panel, 2015)
The safety of caffeine has been recently evaluated by the NDA Panel. According to this assessment
referring to all dietary sources of caffeine and not only to its use as a ﬂavouring substance, an intake
up to 400 mg/person per day is safe for healthy adults. For pregnant and lactating women, an intake
of 200 mg/day does not raise safety concerns for the fetus and breastfed infant, respectively. An
(acute) intake of 3 mg/kg bw per day may serve as a basis to derive daily caffeine intakes of no
concern for children and adolescents (EFSA NDA Panel, 2015).
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